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Stroke is a major cause of morbidity in the industrialized world. It often results not only in 
physical disability, but also in significant cognitive impairment or dementia. Between 10 
and 40% of patients with a recent stroke develop dementia.1-4 Although stroke was already 
recognized as an important cause of dementia more than one hundred years ago, research 
on determinants of poststroke dementia and the cognitive profile of dementia after a stroke 
has strongly intensified during the last decade.
The diagnosis of dementia after a stroke is complex and poses clinicians for several problems. 
Poststroke dementia is a clinical entity with very heterogeneous cognitive disturbances, that 
may be characterized as cortical or subcortical, or a combination of the two. Furthermore, 
cognitive functioning may be hampered by the somatic symptoms that often accompany a 
stroke. In clinical practice, cognitive screening instruments take an important place, either 
to select patients who need further neuropsychological testing or as a diagnostic test in 
patients with obvious dementia. Most existing screening instruments that are used in a 
clinical setting, however, are developed to detect dementia compatible with Alzheimer’s 
disease and their value in detecting dementia after stroke is less well known.
In this thesis, I describe and discuss the diagnosis of dementia after stroke, with emphasis 
on the value of screening instruments in the diagnosis of poststroke dementia. I will use the 
terms dementia after stroke and poststroke dementia for any type of dementia that occurs 
after a stroke, irrespective of its presumed cause.
In the prospective hospital-based part of the Dutch Vascular Factors in Dementia study, 
we examined 300 consecutive stroke patients in the acute phase of stroke. We investigated 
which clinically relevant and easily obtainable variables in the acute phase predicted the 
presence of dementia three to nine months after the event (chapter 2). An overview of the 
value of existing dementia screening instruments in the diagnosis of poststroke dementia 
is presented in chapter 3. We determined the feasibility and value of the CAMCOG and the 
MMSE in screening for poststroke dementia (chapter 4), and describe the development of 
a new screening instrument, the R-CAMCOG, a shorter, and easier to administer test, based 
on the original CAMCOG in chapter 5. The external validation of the R-CAMCOG was 
performed in a new prospective study of 121 stroke patients (chapter 6). The usefulness 
of the R-CAMCOG, was compared with the MMSE, an internationally widely used and 
acknowledged screening instrument in chapter 7. Finally, I will discuss the main findings 
and methodological aspects in chapter 8 and summarize our findings in chapter 9.
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AbsTrAcT
Background. It has been estimated that 10 to 40% of patients who suffer a stroke become 
demented. The mechanisms underlying poststroke dementia or the independent effect of 
vascular risk factors are not yet completely understood. In view of the high incidence of 
dementia after a stroke and the progress in the development of therapeutic agents it is 
important to early select stroke patients with a high risk of dementia. We studied whether 
easily obtainable clinical information after acute stroke is useful in predicting poststroke 
dementia.
Methods. From 1993 to 1996 we studied a prospective and consecutive hospital-based cohort 
of 291 acute stroke patients. The diagnosis of dementia at 3 to 9 months after the onset of 
stroke was based on the results of an extensive neuropsychological examination, clinical 
presentation, information from a close relative and the score on the Blessed dementia scale. 
A final judgment of cognitive functioning was made by a diagnostic panel consisting of two 
neurologists, a neuropsychologist and a trained physician. For the assessment of dementia, 
the criteria of the DSM-III-R were used. We performed multiple logistic regression analyses 
to determine which variables were independently associated with dementia after stroke. We 
then constructed a final prediction model consisting of clinically and statistically significant 
and consistent variables.
Results. Of the 291 patients, 62 (21%) were demented. The final model for early prediction 
of poststroke dementia included age, sex, years of education, previous stroke, white matter 
lesions on CT scan, neglect, hemorrhage on CT scan, mean arterial blood pressure, and 
atrial fibrillation. ROC analysis showed that the area under the curve for this model was 
0.82, with a high specificity and a moderate sensitivity (resp. 95% and 37%), at the 50% 
threshold of the diagnostic probabilities (positive predictive value: 70%, negative predictive 
value: 85%).
Conclusions. Easily available clinical variables, obtained shortly after acute stroke, can be 
used to predict poststroke dementia.
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InTroducTIon
Cerebrovascular disease is one of the most important causes of dementia in Europe and 
North America.2 3 Several studies have estimated that 10 to 40% of patients who suffered 
a stroke become demented.4-7 The mechanisms underlying poststroke dementia or the 
independent effect of vascular risk factors, however, are not yet completely understood. In 
view of the high incidence of dementia after a stroke and progresses in the development 
of therapeutic strategies it is important to be able to early select stroke patients with a high 
risk of dementia for further diagnostic work up, to facilitate appropriate medical attendance 
or medical therapy.
The results of recent studies regarding the possible associations of stroke and subsequent 
dementia are ambiguous,7-11 which may be explained by differences in study population, 
study design, or the definition of dementia. We conducted a study with emphasis on clinical 
detail. The study was based on a prospective hospital-based cohort of 291 well-defined 
stroke patients who were examined extensively on somatic and cognitive features. Its aim 
was pragmatic; it should answer the question whether clinical information that is easily 
obtainable in the acute phase of stroke is useful in predicting poststroke dementia.
PATIenTs And meThods
Patients
Patients were recruited from the Rotterdam Stroke Databank, a prospective registry of 
patients with a transient ischemic attack (TIA), ischemic stroke or primary intracerebral 
hemorrhage, admitted to the Department of Neurology of a large university hospital. From 
March 1, 1993 until January 15, 1996, all patients who met the criteria for enrolment in 
The Dutch Vascular Factors in Dementia Study were entered consecutively.6 Patients had 
to be 55 years or over, and had a TIA with neurological signs on examination, an ischemic 
stroke or intracerebral hemorrhage. Patients were excluded when a reliable assessment of 
dementia could not be made because of aphasia (i.e. a score less than 3 on the Aphasia 
Severity Rating Scale from the Boston Diagnostic Aphasia Examination [BDAE]),12 severe 
sensory handicaps (e.g. deafness or blindness), persistent impairment in consciousness, 
severe psychiatric symptoms, or insufficient command of the Dutch language. Additional 
exclusions were a TIA without neurological signs, concomitant primary cerebral disorder 
or severe co-morbidity with a short life expectancy. Informed consent was obtained from 
all patients or from close relatives in case of impaired judgment.
For the present study we excluded patients with a pre-existent moderate or severe 
dementia.
Procedure
The clinical and demographic characteristics of the patients at baseline were assessed 
immediately after admission to the hospital. We obtained detailed information on 
demographic variables, cardiovascular risk factors, stroke characteristics, and premorbid 
mental and physical status. In addition to a full neurological examination, ancillary 
investigations consisted of standardized blood tests, chest x-ray, computed tomographic 
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scanning and/or magnetic resonance imaging of the brain, duplex scanning of the carotid 
arteries, and a cardiac analysis.
Demographic characteristics
Demographic characteristics included age, sex, and education, which was categorized by 
the number of years of schooling completed.
Cardiovascular risk factors
Hypertension was defined as previously diagnosed and treated hypertension or hypertension 
at casual reading during admission, but al least 24 hours after onset of symptoms (e.g. 
systolic pressure (SBP) >180 mmHg and/or diastolic pressure (DBP) >110 Hg). We also 
calculated the mean arterial blood pressure (MAP) through the standard formula DBP + 
1/3*(SBP –DBP). Diabetes was defined as previously diagnosed and treated diabetes or a 
fasting glucose ≥7 mmol/L. Hypercholesterolemia was defined as a previously diagnosed 
and treated hypercholesterolemia, a serum cholesterol ≥6.0, or a serum cholesterol/HDL 
ratio >5.5.
Previous and present vascular diseases
These data included peripheral vascular disease (e.g. intermittent claudication or peripheral 
vascular surgery), previous hemorrhagic or ischemic stroke, cardiac disease (e.g. angina 
pectoris, myocardial infarction, coronary artery bypass grafting, congestive heart failure, 
and atrial fibrillation).
Type of stroke
Type of stroke was categorized as TIA, ischemic stroke or primary intracerebral hemorrhage, 
and site of stroke was noted as right or left hemispheric or infratentorial. Etiology of stroke 
was classified according to the TOAST criteria.13
Premorbid and present cognitive functioning
Premorbid cognitive functioning was established by a careful interview with a close relative 
and the score on the Blessed dementia scale.14 Severity of dementia was assessed with 
the Blessed Dementia Scale, e.g. a score of >4 indicates moderate dementia, a score of >6 
severe dementia.
Neuropsychological examination
An extensive neuropsychological examination was carried out in all patients in whom 
there was any suspicion of dementia or cognitive decline. If patients were not testable 
due to cognitive deficits or in case they refused further co-operation, the extensive 
neuropsychological evaluation was not performed. In some patients only a limited number 
of tests could be administered. The extensive neuropsychological examination consisted 
of an intelligence test, either the shortened version of the Groninger Intelligence Test,15 a 
Dutch intelligence test, or when this was not administrable Raven’s Coloured Matrices,16 a 
non-verbal intelligence test. The shortened form of the Boston Naming Test (CERAD)17 was 
used to examine word-finding difficulties. Memory was evaluated with Word List Memory 
(CERAD),17 and the Rivermead Behavioural Memory Test.18 We used Digit Span forward and 
backward (WAIS)19 to assess the span of immediate verbal recall, but also as a measure for 
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attentional capacity. Parts of the Trail Making Test,20 and the Stroop Color Word Test21 too 
were used to examine attention. Scores on verbal fluency (animals, occupations, letter B), 
Stroop Color Word Test part III,21 Trail Making Test B,20 served as indication for the level of 
executive functioning. Proverbs and similarities (WAIS)19 provided a measure for abstraction 
and verbal concept formation. Visuo-constructive ability was examined by copying the 
drawing of a circle, diamond, two overlapping rectangles and a cube (CERAD).17 Visual 
perception and spatial orientation were examined by Judgment of Line Orientation.22
Diagnosis of dementia
The diagnosis of dementia at 3 to 9 months after the onset of stroke was based on the 
results of an extensive neuropsychological examination, clinical presentation, information 
from a close relative and the score on the Blessed dementia scale. A final judgment of 
cognitive functioning was made by a diagnostic panel consisting of two neurologists, a 
neuropsychologist and a trained physician. For the assessment of dementia, the criteria of 
the DSM-III-R1 were used. A further sub-classification of dementia was made according to 
the research criteria of the NINDS-AIREN international workshop.23
sTATIsTIcAl AnAlysIs
To determine the clinical correlates of dementia in relation to stroke, we compared the 
characteristics of demented and not-demented patients using chi-square analyses or 
Student’s t-test where appropriate. We performed a multiple logistic regression analysis 
with all variables that were statistically significant (p<0.10) in the univariate analyses. Then, 
we excluded variables with a large number of missing values or overlapping measures, 
and constructed a model, that was based on variables that were considered to have a 
consistent and clinically relevant association with poststroke dementia, as judged from 
previous studies and clinical experience. In this way, we avoided the pitfalls of stepwise 
selection procedures.24
resulTs
The number and origin of patients excluded from the study population is represented in 
Figure 1. From the 825 patients registered in the Rotterdam Stroke Databank, approximately 
a quarter was younger than 55 years of age, 15% died within three months after stroke 
onset, 5% had a transient ischemic attack without any sign on neurological examination, 
and another 5% had severe aphasia. One tenth was excluded for various other reasons (e.g. 
moved out of the region, did not speak Dutch, or had a short life expectancy due to other 
diseases), and 5% did not give informed consent. Of the 300 remaining patients, 9 had a 
moderate or severe dementia before the most recent stroke and were excluded from the 
present study. Overall, 21% of the patients were demented 3 to 9 months after stroke.
The demographic characteristics of the 291 study patients are summarized in Table 1. 
The demented patients were on average 5 years older than not-demented patients and 
had on average 1.6 years less education. There were no differences between demented 
and not-demented patients with regard to the presence of hypertension and diabetes. 
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Serum cholesterol level was inversely related to dementia three to nine months after stroke 
(p<0.001). Atrial fibrillation, previous stroke and use of alcohol were significantly associated 
with the presence of dementia. Table 2 shows the stroke features in both groups. About 
three-quarters of the patients suffered an ischemic stroke. Of the patients presenting with 
TIA, only 3 (7%) became demented three to nine months after stroke. Of the patients 
with an ischemic stroke 46 (22%) were demented, whereas 13 (37%) patients with an 
intracerebral hemorrhage were demented at 3 to 9 months. White matter lesions were 
present in about half of the demented patients, but only in one fifth of the not-demented 
patients. Demented patients suffered more often from an ischemic stroke as a consequence 
of a cardiac embolism (27% vs. 17%), whereas in the not-demented group large artery 
atherosclerosis and small vessel disease were more frequent. Neglect in the acute phase 
was strongly associated with dementia 3 to 9 months after stroke.
We performed a multiple regression analysis in which we included all variables that were 
associated with dementia in the univariate analyses (p<0.10). Because our main purpose was 
to establish which easily obtainable clinical information in acute stroke predicts poststroke 
Table 1. Demographic variables and vascular riskfactors
Demented
(N=62)
Not-demented
(N=229)
Total studygroup
(N=291)
P
Age * 73.4 (7.2) 68.2 (8.0) 69.3 (8.1) <0.001
Years of education* 7.4 (3.1) 9.0 (3.0) 8.7 (3.1) <0.001
Female sex 31 (50) 84 (37) 115 (40) 0.06
Hypertension 51 (82) 202 (88) 253 (87) 0.22
Systolic blood pressure* 167.1 (29.4) 170.7 (30.0) 170.0 (29.9) 0.39
MAP* 118.5 (18.5) 121.1 (18.6) 120.6 (18.6) 0.33
Diastolic blood pressure* 94.2 (15.6) 96.3 (16.2) 95.9 (16.1) 0.37
Diabetes 16 (26) 50 (22) 66 (23) 0.51
Hyperlipidemia 38 (61) 171 (75) 209 (72) 0.04
Total cholesterol* 5.53 (1.3) 6.27 (1.2) 6.11 (1.2) <0.001
Peripheral vascular disease 3 (5) 33 (14) 36 (12) 0.04
Atrial fibrillation 15 (24) 30 (13) 45 (15) 0.03
Angina pectoris 13 (21) 28 (12) 41 (14) 0.08
Congestive heart failure 6 (10) 12 (5) 18 (6) 0.20
Myocardial infarction 8 (13) 37 (16) 45 (15) 0.53
CABG 2 (3) 14 (6) 16 (6) 0.38
Previous stroke 21 (34) 42 (18) 63 (22) 0.008
Smoking 16 (26) 88 (38) 104 (36) 0.07
Alcohol consumption 17 (27) 109 (48) 126 (43) 0.004
Values are number of patients with percentages in parentheses
* Values are means with standard deviations in parentheses
MAP: mean arterial bloodpressure DBP + 1/3 x (SBP –DBP)
CABG: coronary artery bypass graft
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Table 2. Stroke features in demented and not-demented patients
demented
(n=62)
not-demented
(n=229)
Total studygroup
(n=291)
P
Type of stroke
TIA
Ischemic stroke
Intracerebral hemorrhage
3 (5)
46 (74)
13 (21)
43 (19)
164 (71)
22 (10)
46 (16)
210 (72)
35 (12) 0.004
site of stroke
Right hemisphere
Left hemisphere
Infratentorial
32 (52)
18 (29)
12 (19)
104 (45)
100 (44)
25 (11)
136 (47)
118 (40)
37 (13) 0.06
clinical features
Lowered consciousness
Neglect
Aphasia 
6 (10)
24 (39)
9 (15)
8 (4)
36 (16)
32 (14)
14 (5)
60 (21)
41 (14)
0.05
<0.001
0.81
white matter lesions 28 (45) 44 (19) 72 (25) <0.001
cause of ischemic stroke
Large artery atherosclerosis
Cardiac embolism
Small vessel disease
Other
Incomplete investigation 
9 (18)
13 (27)
11 (22)
1 (2)
15 (31)
49 (24)
35 (17)
67 (32)
11 (5)
45 (22)
58 (23)
48 (19)
78 (30)
12 (5)
60 (23) 0.20
Figuur 1, hoofdstuk 2 
 
Figure 1. Selection of patients for the present study 
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Figure 1. Selection of patients for the present study
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dementia, we constructed a clinically sensible model. We therefore first included variables 
that were associated (p<0.1) with the presence of dementia in the univariate analyses, e.g. 
age, years of education, sex, cholesterol level, atrial fibrillation, angina pectoris, congestive 
heart failure, previous stroke, smoking, use of alcohol, type of stroke, site of stroke, 
lowered consciousness level, neglect, white matter lesions, and hemorrhage. Next, we 
added variables that did not reach significance in the univariate analysis but were regarded 
as clinically sensible based on the results of previous studies or clinical experience. The 
final model, the clinically sensible model, consisted of the following prognostic factors: 
age, sex, years of education, previous stroke, presence of leukoaraiosis on CT, neglect, 
MAP, atrial fibrillation, and hemorrhagic stroke. ROC analysis showed that the diagnostic 
accuracy of this model was 0.82, with a high specificity and a moderate sensitivity (resp. 
95% and 37%), at the 50% threshold of the diagnostic probabilities (positive predictive 
value: 70%, negative predictive value: 85%).
dIscussIon
We investigated in a carefully examined hospital-based stroke population whether 
commonly available clinical variables are useful in predicting the presence of dementia 3 
to 9 months after a stroke. In univariate analyses we found strong associations with age, 
years of education, sex, level of cholesterol (inverse relation), congestive heart failure, atrial 
fibrillation, previous stroke, alcohol consumption, neglect, type of stroke, cause of ischemic 
stroke, and white matter lesions on CT scan. We constructed a clinically sensible model, 
based on significant variables in univariate analyses and clinically relevant variables. This 
model, which included age, sex, years of education, white matter lesions on CT, neglect, 
intracerebral hemorrhage, MAP, and atrial fibrillation as risk factors for the presence of 
poststroke dementia, had an acceptable diagnostic accuracy.
Several prospective hospital-based studies have been conducted to unravel the question 
which patients are at risk for dementia after stroke. The results of these studies, however, are 
ambiguous. This is likely due to differences in study populations, definitions of concepts, 
different methods, or the use of different criteria for the diagnosis of dementia. Our purpose 
Table 3. Predictors of poststroke dementia in a multiple regression model
odds ratio (95% cI)
Age* 1.06 (1.0 – 1.1)
Years of education* 0.9 (0.8 – 1.0)
Female sex† 1.3 (0.7 – 2.6)
MAP (mmHg) ‡ 0.98 (0.96 – 1.0)
White matter lesions † 3.0 (1.7 – 5.3)
Neglect† 3.1 (1.5 – 6.3)
Previous stroke 2.1 (1.0 - 4.4)
Hemorrhagic stroke† 2.3 (0.9 – 5.6)
Atrial fibrillation† 2.4 (1.0 – 5.6)
* odds ratio per year increase, † odds ratio: presence of variable ‡ odds ratio per unit increase
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was to design a pragmatic and feasible prognostic model with clinical variables that are 
easy to obtain in patients with acute stroke.
As we wanted to establish the relationship between a stroke and the development of 
poststroke dementia, we excluded patients with a previously diagnosed moderate or severe 
dementia (3%) to preclude confounding. The majority of these patients had a diagnosis of 
probable Alzheimer’s disease. We did not exclude patients with pre-existent mild dementia 
or cognitive impairment, as more subtle cognitive disturbances may easily be overlooked 
either by patients or their relatives or by the attending physicians. The proportion of all 
patients with pre-existent dementia in our study (7%) is somewhat lower than in previous 
studies.4 7 25 26 There are, however, large variations in the numbers of pre-existent dementia 
in these studies, probably due to selection or recruitment bias. Dementia was present in 
21.3% of the remaining patients in the present study. The large variation in the prevalence 
of poststroke dementia in previous studies, ranging from 6% to 32%,10 27 is due to differences 
in study design, particularly the in- and exclusion criteria, the information on which the 
diagnosis of dementia was based and the criteria for dementia used. The strength of our 
study is that we performed an extensive neuropsychological examination in each patient 
with any suspicion of cognitive decline. Furthermore, we conducted a careful interview 
with the patient and a close informant to establish the severity of cognitive decline, onset 
and course.
The diagnosis was made three to nine months after stroke to overcome acute and transient 
symptoms. In a multidisciplinary diagnostic panel the diagnosis was based on the results of 
an extensive neuropsychological examination, and information from an interview with the 
patient and a close informant.
In accordance with most other studies, we found that advancing age,7 8 10 11 and years of 
education7 8 10 11 were related to the presence of dementia in univariate analyses. Female 
sex was related to the presence of poststroke dementia in our study, but only Barba et al. 
have reported this before.7
Some well-established vascular risk factors, such as hypertension, diabetes mellitus, 
myocardial infarction, and smoking were not related to poststroke dementia in our sample. 
Some previous studies did find a relation with diabetes,8 9 or smoking,10 but others did not. 
Although hypertension is a known vascular risk factor, there are no studies that report a 
direct association with poststroke dementia. However, our study indicates a protective 
effect of increased blood pressure, perhaps because low bloodpressure leads to relative 
hypoperfusion and more cerebral damage in this category of patients. In our study, level of 
cholesterol was inversely related to the presence of dementia. Demented patients had on 
average a lower cholesterol level than not-demented patients (5.4 mmol/L vs. 6.3 mmol/L). 
One study also found that hypercholesterolemia was a more frequent symptom among 
not-demented patients,10 but others did not.7 8 11 An explanation for our finding may be 
that demented patients were older whilst the level of cholesterol is known to be inversely 
related with age. Another explanation may be that not-demented patients have a higher 
body weight, simply because they eat more. However, after adjustment for body weight or 
age, the relationship between cholesterol level and poststroke dementia remained intact. 
Interestingly, in the study of Dyker et al, low cholesterol levels were an adverse prognostic 
factor for survival in acute stroke patients.28 In our opinion, the association between lower 
level of cholesterol and increased risk of dementia may be real, albeit unexplained, and 
needs to be investigated in explorative studies. However, as we could not find a plausible 
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explanation for the association between level of cholesterol and poststroke dementia, and 
taking into account the conflicting results of other studies, we cannot exclude that the 
association of level of cholesterol with poststroke dementia in our study may be due to a 
yet unknown confounding mechanism.
Neglect in the acute phase proved a strong independent prognostic factor for poststroke 
dementia 3 to 9 months after a stroke. When neglect was still present at the time of 
the neuropsychological examination, and scores on some tests were influenced by the 
hemi-inattention, we judged the results of other tests on the same cognitive domain. The 
presence of neglect therefore did not confound the diagnosis of dementia. Only a few other 
studies have included neglect as a clinical variable.
As in most other studies we excluded patients with a moderate or severe aphasia, 
because this would hinder a reliable judgment of cognitive functioning. The presence of 
mild aphasia was not related to poststroke dementia in our study, which is in agreement 
with the study of Tatemichi et al.8 Other studies reported an association between aphasia 
and poststroke dementia, but this can be explained by different in- and exclusion criteria. 
In one study, all aphasic patients, including patients with a severe aphasia were analyzed.9 
whereas in another, severe aphasia served as an exclusion criterion, but this was only 
judged on clinical grounds.10
Previous stroke is a frequently found clinical determinant of poststroke dementia,8 10 29 
which was confirmed by our data. Atrial fibrillation has been reported as an independent 
risk factor for dementia in several studies,9 25 also confirmed by our results.30 In our study, 
poststroke dementia was related to the site and type of stroke, but not to the cause of 
ischemic stroke. We found an increased risk for dementia in patients with an intracerebral 
hemorrhage, whereas patients with a TIA had a considerable lower risk of dementia. Left 
hemispheric stroke was associated with a lower risk of dementia, which refutes the findings 
of other studies.8 10 The presence of white matter lesions on CT scan was associated with an 
increased risk of poststroke dementia, in accordance with previous studies.11 31 32
The predictors of poststroke dementia in our final multiple regression model are variables 
that are easy to assess and obtained on a routine basis in most neurological departments. 
This makes the model feasible and of practical value in predicting poststroke dementia. 
A drawback of the model, reflecting our focus on clinical variables, is the absence of 
other determinants, such as biochemical markers, or detailed MRI variables, which may 
also be strong predictors of poststroke dementia.33 Furthermore, although the diagnosis 
of dementia was carefully made by a multidisciplinary panel, the dementia syndrome and 
type of dementia were not pathologically verified, which possibly led to misclassification 
of the type of dementia. Of course, this prediction model should be evaluated in a new 
independent dataset before it is used routinely.
Despite these limitations, the present study may provide more insight in the clinical 
determinants of poststroke dementia and may stimulate further research into its underlying 
mechanisms.
Predictors of poststroke dementia 25
references
 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 
Washington, DC: American Psychiatric Association, 1987.
 2. Leys D, Pasquier F, Parnetti L. Epidemiology of vascular dementia. Haemostasis 1998;28: 
134-50.
 3. Roman GC. Vascular dementia may be the most common form of dementia in the elderly. J 
Neurol Sci 2002;203-204:7-10.
 4. Tatemichi TK, Desmond DW, Mayeux R, Paik M, Stern Y, Sano M, Remien RH, Williams JB, 
Mohr JP, Hauser WA. Dementia after stroke: baseline frequency, risks, and clinical features in a 
hospitalized cohort. Neurology 1992;42:1185-93.
 5. Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M. Dementia three months after stroke. Baseline 
frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory 
Study (SAM) cohort. Stroke 1997;28:785-92.
 6. van Kooten F, Bots ML, Breteler MM, Haverkate F, van Swieten JC, Grobbee DE, Koudstaal 
PJ, Kluft C. The Dutch Vascular Factors in Dementia Study: rationale and design. J Neurol 
1998;245:32-9.
 7. Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T. Poststroke 
dementia: clinical features and risk factors. Stroke: 2001;31:1494-501.
 8. Tatemichi TK, Desmond DW, Paik M, Figueroa M, Gropen TI, Stern Y, Sano M, Remien R, 
Williams JB, Mohr JP. Clinical determinants of dementia related to stroke. Ann Neurol 
1993;33:568-75.
 9. Censori B, Manara O, Agostinis C, Camerlingo M, Casto L, Galavotti B, Partziguian T, Servalli 
MC, Cesana B, Belloni G, Mamoli A. Dementia after first stroke. Stroke 1996;27:1205-10.
 10. Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M. Clinical determinants of 
poststroke dementia. Stroke 1998;29:75-81.
 11. Tang WK, Chan SS, Chiu HF, Ungvari GS, Wong KS, Kwok TC, Mok V, Wong KT, Richards 
PS, Ahuja AT. Frequency and determinants of poststroke dementia in Chinese. Stroke 2004;35: 
930-5.
 12. Goodglass H, Kaplan E. The assessment of aphasia and related disorders. Philadelphia: Lea & 
Febiger, 1983.
 13. Adams HP, Jr., Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE, III. 
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical 
trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
 14. Blessed G, Black SE, Butler T, Kay DW. The diagnosis of dementia in the elderly. A comparison 
of CAMCOG (the cognitive section of CAMDEX), the AGECAT program, DSM-III, the Mini-
Mental State Examination and some short rating scales. Br J Psychiatry 1991;8:193-8.
 15. Luteijn F, Vanderploeg FAE. Groninger Intelligentie Test Manual. Lisse, The Netherlands: Swets 
& Zeitlinger, 1983.
 16. Raven JC. Guide to Using the Coloured Progressive Matrices. London, UK: HK Lewis, 1965.
 17. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C. 
The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part I. Clinical and 
neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39:1159-65.
 18. Wilson BA, Cockburn J, Baddeley AD. Rivermead Behavioural Memory Test. Reading, UK: 
Thames Valley Test Company, 1985.
 19. Wechsler D, Stone C. Manual for the Wechsler Adult Intelligence Scale. New York, NY: The 
Psychological Corporation, 1955.
 20. Reitan RM. Validity of the Trail Making Test as an indication of organic brain damage. Percept 
Mot Skills 1958;8:271-6.
 21. Hammes JGW. Stroop kleur-woord Test: Dutch manual. Lisse, The Netherlands: Swets & 
Zeitlinger, 1978.
 22. Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. Arch Neurol 
1978;35:364-7.
26
Ch
ap
te
r 2
 23. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, Amaducci L, 
Orgogozo JM, Brun A, Hofman A. Vascular dementia: diagnostic criteria for research studies. 
Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
 24. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modeling with logistic 
regression analysis: in search of a sensible strategy in small data sets. Med Decis Making 
2001;21:45-56.
 25. Inzitari D, Di Carlo A, Pracucci G, Lamassa M, Vanni P, Romanelli M, Spolveri S, Adriani P, 
Meucci I, Landini G, Ghetti A. Incidence and determinants of poststroke dementia as defined 
by an informant interview method in a hospital-based stroke registry. Stroke 1998;29:2087-93.
 26. Henon H, Pasquier F, Durieu I, Godefroy O, Lucas C, Lebert F, Leys D. Preexisting dementia in 
stroke patients. Baseline frequency, associated factors, and outcome. Stroke 1997;28:2429-36.
 27. Madureira S, Guerreiro M, Ferro JM. Dementia and cognitive impairment three months after 
stroke. Eur J Neurol 2001;8:621-7.
 28. Dyker AG, Weir CJ, Lees KR. Influence of cholesterol on survival after stroke: retrospective 
study. BMJ 1997;314:1584-8.
 29. Tatemichi TK, Desmond DW, Paitz M. The ‘Mini-Mental State’ Examination as a screen for 
dementia following stroke [abstract]. J Clin Exp Neuropsychol 1991;13:419A.
 30. Moroney JT, Bagiella E, Desmond DW, Paik MC, Stern Y, Tatemichi TK. Risk factors for incident 
dementia after stroke. Role of hypoxic and ischemic disorders. Stroke 1996;27:1283-9.
 31. Tatemichi TK, Paik M, Bagiella E, Desmond DW, Stern Y, Sano M, Hauser WA, Mayeux R. Risk 
of dementia after stroke in a hospitalized cohort: results of a longitudinal study. Neurology 
1994;44:1885-91.
 32. Leys D, Henon H, Pasquier F. White matter changes and poststroke dementia. Dement Geriatr 
Cogn Disord 1998;9 Suppl 1:25-9.
 33. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts 
and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215-22.
The value of screening instruments in 
the diagnosis of poststroke 
dementia
 
chapter 3
28
Ch
ap
te
r 3
AbsTrAcT
Brief dementia screening instruments, or mental status tests are frequently used to screen 
for cognitive impairment. We discuss the strengths and weaknesses of existing mental 
status tests in dementia screening in general. Most screening instruments that are used in 
clinical practice are developed to detect dementia compatible with Alzheimer’s disease 
and their value in detecting dementia after stroke is less well known. A stroke may cause 
both cortical and subcortical deficits and the clinical expression of poststroke dementia is 
different from that of Alzheimer’s disease. Existing brief mental status tests have limited 
value in this patient group because they tend to ignore specific problems which may 
occur in stroke patients. Some expanded screening instruments, like the CAMCOG, are 
more useful and have additional diagnostic value. With the growing interest in research for 
vascular factors in dementia over the past years, however, a specific screening instrument 
for poststroke dementia would be a valuable contribution.
Value of screening instruments in poststroke dementia 29
InTroducTIon
With the aging of the population in industrialized countries, the prevalence of dementia has 
increased dramatically in the past 20 years and is expected to continue to increase further 
during the early 21st century, placing a heavy burden on public health care resources. 
The most important cause of dementia is Alzheimer’s disease, followed by cerebrovascular 
diseases.1 2 Although recent studies suggest that various vascular mechanisms also play 
a significant role in Alzheimer’s disease, the clinical expression and management of 
vascular dementia and Alzheimer’s disease are usually very different. Early detection and 
differentiation of dementia is important from a psychosocial point of view and with respect 
to management of the dementia syndrome.
Cognitive deterioration is by definition a central feature of dementia and the diagnosis 
of dementia therefore completely relies on the assessment of cognitive functioning. A 
clinical investigation, which includes an interview with the patient and a close informant, is 
important, but psychometric assessment of cognitive functioning is necessary in many cases 
to support clinical judgment and quantify the cognitive deficits. Brief screening instruments, 
or mental status tests, can provide insight in the presence of cognitive impairment in a 
quick and convenient way and are frequently used to screen for cognitive impairment. 
Although these tests do not provide the same amount and type of information as a full 
neuropsychological examination, they may be used for selecting patients in whom such 
an extended neuropsychological examination is deemed necessary. For many seriously 
impaired patients, the mental status examination may not only be the examination 
of choice, but may also be the only examination that can be made of these patients’ 
neuropsychological condition. Mental status tests by no means replace formal testing; rather 
do they serve another goal.
In this review, we will briefly describe the clinical differences between Alzheimer’s 
disease and vascular dementia, especially poststroke dementia, and discuss the diagnostic 
criteria. It is beyond the scope of this article to review all dementia screening tests, but 
we will discuss the strengths and weaknesses of these tests in general. Furthermore, we 
will evaluate the factors that have to be taken into account when screening for cognitive 
impairment after stroke. We will discuss the feasibility of existing tests in stroke patients 
and their ability to differentiate between dementia in Alzheimer’s disease and vascular 
dementia, in particular dementia after stroke.
demenTIA
Dementia is an acquired clinical syndrome with cognitive deterioration as a central feature. 
It has various underlying causes, but Alzheimer’s disease and vascular dementia are most 
common. Dementia caused by Alzheimer’s disease is a typical cortical dementia and is 
characterized by memory deficits and decline of at least one other cognitive function in 
comparison with the patient’s previous level of functioning as determined by a history 
of decline in performance and by abnormalities noted from clinical examination and 
neuropsychological tests. The diagnosis of dementia cannot be made when consciousness 
is impaired by delirium, drowsiness, stupor or coma, or when other clinical abnormalities 
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prevent adequate evaluation of mental status beside the presence of dementia.3 4 According 
to the DSM-III-R, but not the NINCDS/ADRDA criteria, the cognitive deficits should be 
severe enough to interfere with daily functioning. To fulfil the criteria for Alzheimer’s 
disease of the DSM-III-R and NINCDS/ADRDA the dementia must have an insidious onset 
and a gradual progressive course, and all other possible causes for dementia must be 
excluded.
The dementia syndrome associated with cerebrovascular disease, vascular dementia, 
has a variety of etiologies and is the most important cause of dementia after Alzheimer’s 
disease. The causes include one or multiple infarcts, a single strategic infarct, small vessel 
disease, hemorrhagic strokes and hypoperfusion. Poststroke dementia is a heterogeneous 
syndrome and there may be deficits in any cognitive domain. The dementia syndrome may 
be classified as subcortical in some and cortical in others, while a combination of cortical 
and subcortical deficits is also possible. A combination of Alzheimer’s disease with vascular 
dementia is also known.
Research criteria for vascular dementia have been designed by the NINDS-AIREN 
International Workshop5 and consist of: presence of a dementia syndrome and 
cerebrovascular disease and a relationship between those two disorders. The criteria for 
a dementia syndrome are adopted from the World Health Organization (WHO) and are 
defined as a cognitive decline from a previous higher level of functioning and manifested 
by impairment of memory and two or more other cognitive domains. These domains 
include orientation, attention, language, visuo-spatial functions, executive functions, motor 
control and praxis, preferably established by clinical examination and documented by 
neuropsychological testing. The deficits should be severe enough to interfere with daily 
living. Exclusion criteria for dementia include cases with disturbed consciousness, delirium, 
psychosis, severe aphasia or major sensorimotor impairment precluding neuropsychological 
testing. The presence of cerebrovascular disease is defined by the presence of focal signs on 
neurological examination consistent with stroke, and evidence of relevant cerebrovascular 
disease by brain imaging. A relationship between cerebrovascular disease and dementia 
may be inferred when dementia onset is within three months after stroke, of a history of 
abrupt deterioration in cognitive functions, of fluctuating, stepwise progression of cognitive 
deficits.
demenTIA screenIng TesTs
A dementia screening test is a psychometric test that ideally should give an objective and 
standardized judgment of present cognitive functioning and has to be able to differentiate 
adequately between normal and impaired cognitive functioning. Psychometric tests 
should provide a quantitative observation that satisfies the demands of reliability, which 
refers to the consistency and reproducibility of a result, and validity, which addresses the 
question whether the test measures the relevant abnormality. Another important issue is the 
diagnostic accuracy of a test, which reflects the test’s ability to correctly classify patients. 
The sensitivity, i.e. the ability of a test to detect subjects with true cognitive deterioration, 
and specificity, the ability to correctly identify the absence of cognitive deterioration, should 
be satisfactory. The desirable ratio of sensitivity and specificity can differ depending on the 
setting. Sensitivity is generally considered to be of primary importance when screening 
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for the presence of cognitive impairment. The relative hazards of false negative errors 
are thought to be greater than those of false positive errors. In most settings, it is more 
important not to miss patients with true cognitive deterioration, than to misclassify a patient 
without cognitive impairment, which may only lead to unnecessary follow up testing. 
Though specificity is of secondary importance in a screening situation, moderately high 
specificity is needed to make cognitive screening useful and informative.
Apart from the concerns of reliability, validity and diagnostic accuracy, efficiency and cost 
effectiveness are given high priority in screening for dementia. The screening instruments 
have to be relatively brief and easy to administer.
generAl remArKs regArdIng demenTIA screenIng InsTrumenTs
Dementia screening instruments that are used in clinical practice are similar in many 
ways. Each test is a subset from a larger set of items. Most brief screening instruments 
have been developed for the detection of dementia of the Alzheimer type and focus on 
orientation, memory and higher cortical functions like aphasia, apraxia and agnosia. In the 
past, several mental status tests have been developed for this purpose, such as the Mini 
Mental State Examination (MMSE),6 Mental Status Questionnaire (MSQ),7 Short Portable 
Mental Status Questionnaire (SPMSQ),8 Cognitive Capacity Screening Examination (CCSE),9 
and the Short Blessed Test.10 The MMSE, which is by far the most widely used screening 
instrument for dementia, has proven to be a reliable and valid screening instrument in large 
epidemiological studies of dementia. It is also a frequently used screening instrument in 
clinical settings, and although it has obvious benefits in screening for cognitive impairment, 
several serious limitations have been noted.11 Most studies with respect to reliability and 
validity of brief mental status tests concerns the MMSE, but the benefits and weaknesses are 
probably valid for all brief mental screening tests. Strengths of dementia screening tests are 
that they are brief, inexpensive and easy to administer. Obviously the administration and 
interpretation of these tests requires less training and need not necessarily be performed by 
a neuropsychologist. An additional benefit of brief screening instruments is that they tend 
to be less unpleasant and intrusive for older patients. Mental status tests are generally able 
to differentiate dementia from pseudodementia, a pattern of dysfunctional behavior that 
closely resembles dementia. Reported weaknesses concern the influence of age, education 
and (socio)cultural variables on testscores. Previous studies suggest that age and education 
are associated with dementia,12-15 and also with the performance on the brief mental status 
tests.16-18 Poorly educated elderly people are much more likely to fail on these tests. Cultural 
differences influence test performance and increase the risk of false positive scores.19 20 
Apart from these sociodemographic factors there are several other variables responsible for 
false positive errors: somatic illness (e.g. diabetes mellitus, Parkinson’ s disease or stroke) 
and depression are related to lower scores on mental status tests.21 It is also suggested 
that sensory handicaps, in particular visual problems, influence testscores.22 A common 
critique is that most brief screening instruments are not sensitive enough to detect mild 
cognitive impairment: they are suitable to discriminate between moderate dementia and 
normal cognitive functioning, but not in separating mildly demented patients from normal 
subjects.23 These tests also are less suitable to determine the stage of deterioration.11 19 Other 
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limitations of brief screening tests is that they are relatively insensitive to focal brain lesions, 
right hemisphere dysfunction, and dementia with frontal lobe involvement.11 17 19 24
The above mentioned weaknesses of brief mental status tests have led to the adjustment 
of existing tests and the development of more comprehensive screening instruments. Teng 
and Chui made an effort to compensate for the weaknesses of the MMSE and developed 
an expanded version of the MMSE, the modified Mini-Mental State (3MS).25 This modified 
version contains the items of the original MMSE but were given a different weight, and 
items such as abstraction and wordfluency were added. Research with the 3MS has been 
limited. Sofar, only slightly better sensitivity than the MMSE but no other significant 
improvements have been reported. The CAMCOG is the cognitive and self-contained part of 
the Cambridge Examination for Mental Disorders of the Elderly (CAMDEX), a standardized 
instrument for the diagnosis and grading of dementia.26 In addition to the MMSE items the 
CAMCOG contains measures such as recognition, abstraction, praxis, and wordfluency. 
Lindeboom et al. reviewed some psychometric properties of the CAMCOG and found that 
is was stable and reliable and differentiated well between normal cognitive functioning 
and mild cognitive impairment.27 A disadvantage of the CAMCOG is, however, that it does 
not differentiate very well in older patients or patients with a low level of education.27 28 
Two other tests deserve mention here: The Neurobehavioral Cognitive Status Examination 
(NCSE)29 and Mattis Dementia Rating Scale (MDRS).30 These tests are also classified as 
screening instrument, although the items are arranged in a different manner. An interesting 
feature of both scales is that, instead of giving the items in the usual ascending order of 
difficulty, the most difficult item is given first as a screen. This instruction can save time in 
a screening examination, but on the other hand one study with the NCSE indicates that the 
screen items produce a relatively high false negative rate and it is recommended that all items 
are administered.31 The NCSE is a general screening instrument for cognitive dysfunction 
and the findings are not summarized in a total score, but in a profile of scores. The NCSE is 
sensitive to the presence of cognitive dysfunction, but there is also moderate overdiagnosis 
of cognitive dysfunction in the elderly patient.32 33 Furthermore, it is suggested that the 
NCSE is equal in its sensitivity, specificity, and diagnostic accuracy in a geriatric population 
to the shorter MMSE.33 The MDRS is particularly sensitive to the cognitive changes that 
characterize dementia of the Alzheimer’s type, with the areas of testing: attention, initiation 
and perseveration, construction, conceptual reasoning and memory. The total score is 
accurate in differentiating mild and moderate dementia from normal subjects,34 35 but the 
MDRS may not be sensitive enough to assess mild dementia in high functioning patients.36 
Age and education have been found to effects the total score of the MDRS.
consIderATIons for demenTIA screenIng AfTer sTroKe
As mentioned, dementia screening instruments that are used in clinical practice are usually 
developed to detect cognitive deficits compatible with Alzheimer’s disease. Aspects of 
cognitive functioning, like slowing of intellectual functioning, abstraction, retrieval, and 
recognition, and visuo-spatial abilities are less well measured. This means that these short 
tests a priori seem less suitable for detecting subcortical dementia caused by Parkinson’s 
disease, normal pressure hydrocephalus, progressive supranuclear palsy, Binswanger 
disease or dementia that may have both cortical and subcortical deficits like dementia after 
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Table 1. Comparison of different dementia screening instruments regarding dementia in general and poststroke dementia in particular
Dementia screening tasks in general Considerations for dementia 
screening in stroke patients
strengths weaknesses
Brief mental status tests
(e.g. 
MMSE, 
MSQ, 
SPMSQ, 
CCSE, 
Short 
Blessed 
test)
–  Brief, inexpensive and easy to 
administer.
–  Less unpleasant and intrusive for 
older patients than longer tests.
–  Generally able to differentiate 
between moderate dementia and 
normal cognitive functioning.
–  Testscores are influenced by 
demographic and cultural 
factors.
–  Somatic illness and sensory 
handicaps influence the scores.
–  Not sensitive enough to 
discriminate between mild 
cognitive impairment from 
normal cognitive functioning.
–  Not suitable for staging 
dementia.
–  Generally not able to 
differentiate between different 
types of dementia.
–  Developed to detect cognitive 
deficits compatible with 
Alzheimer’s disease, and contain 
no or little subcortical elements.
–  Verbally based, and therefore 
underestimating consequences 
of left hemispheric lesions 
and possibly overestimating 
consequences of right 
hemispheric lesion.
Extended mental status tests
3MS –  Relatively brief, and easy to 
administer.
–  By adding and weighing items 
a broader range of cognitive 
abilities can be tested than with 
the MMSE.
–  Focus is still on cortical deficits. –  Despite the addition and 
weighing of items only slightly 
more sensitive than the MMSE in 
a stroke population 
CAMCOG –  Reliable and valid.
–  Able to differentiate between 
mild cognitive impairment and 
normal cognition.
–  Can be used for grading 
dementia.
–  Comprehensive and allows a 
judgment of a large number of 
cognitive domains. 
–  Moderate influence of age and 
educational level.
–  Despite the addition of 
‘subcortical’ items, emphasis 
is still on deficits compatible 
with AD.
–  Restricted number of 
‘subcortical’ items.
–  Constructional tasks (drawing 
and praxis) may be a problem in 
patients with a paresis.
–  Has additional diagnostic value 
in dementia screening in stroke 
population.
NCSE –  Comprehensive and assesses 
several areas of cognitive 
function.
–  Screen items can be a timesaver.
–  Highly sensitive to cognitive 
dysfunctioning.
–  Tends to overdiagnose the 
cognitive deterioration in the 
elderly.
–  Equal in its sensitivity, specificity, 
and diagnostic accuracy in 
a geriatric population to the 
MMSE. 
–  Absence of timed tasks.
–  Tends to overdiagnose ‘organic’ 
deterioration, and may therefore 
be less suitable in screening for 
dementia in a stroke population.
MDRS –  Able to differentiate patients with 
mild and moderate dementia 
from normal subjects.
–  Screen may be a timesaver.
–  Can be used for staging 
dementia.
–  Not sensitive enough to 
assess mild dementia in high 
functioning patients.
–  Moderate influence of age and 
level of education.
–  Especially developed to detect 
cognitive deficits compatible 
with AD, with emphasis on 
orientation, memory, and 
abstraction.
–  The absence of timed tasks and 
other subcortical items makes 
this test not appropriate for 
the purpose of screening for 
poststroke dementia. 
MMSE = Mini Mental State Examination, MSQ = Mental State Questionnaire, SPMSQ = Short Portable Mental State Questionnaire, CCSE = 
Cognitive Capacity Screening Examination, 3MS = Modified version of the Mini Mental State Examination, NCSE = Neurobehavioral Cognitive 
Status Examination, MDRS = Mattis Dementia Rating Scale, AD = Alzheimer’s disease.
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stroke. Moreover, existing dementia screening instruments predominantly contain verbally 
mediated items that tend to exaggerate the extent of cognitive deficits in patients with a 
left hemispheric stroke. Likewise, tests that emphasize verbal capacities may underestimate 
the consequences of right hemispheric lesions.24 37 38 In patients with a stroke, in particular 
a left hemispheric stroke, a paresis can prevent a good performance at items that appeal 
to constructional abilities. Moreover, subtests that refer to praxis, frequently accompanying 
aphasia, can raise problems for stroke patients. In patients with a right-sided hemispheric 
stroke neglect can be a confounding factor in testscores.
With the fast growing interest in research for vascular factors in dementia over the past 
years, the need for specific screening instruments has emerged. To our knowledge, no new 
screening instruments have been developed for detection of poststroke dementia yet and 
all studies use existing screening instruments for dementia. The MMSE is still a frequently 
used mental status test in patients with a recent stroke, but has several disadvantages due 
to its emphasis on language and focus on cortical functions. However, Tatemichi et al. 
used the MMSE as a screening instrument and found that the MMSE can be of use when 
adjustments are made for the false positive rates.39 Still, the absence of tasks sensitive to 
subcortical dysfunction, may make the MMSE a useful, but not ideal screening instrument for 
patients with a recent stroke. The 3MS seems more suitable for the detection of subcortical 
pathology than the MMSE. Grace et al. compared the original MMSE and the modified 
version in a stroke population and found that the 3MS en MMSE had a similar overall 
classification accuracy, which was adequate for patients with left hemispheric strokes and 
poor for patients with right sided strokes.40 The authors, however, believe that the 3MS is a 
clinically more useful screening instrument in stroke patients because its false negative rate 
is lower and it demonstrated a higher sensitivity in a stroke population.
In the Dutch Vascular factors in Dementia Study the CAMCOG was used as a screening 
instrument.41 Although the CAMCOG was also originally designed to diagnose primary 
degenerative dementia, it has an advantage over brief screening tests that it covers a 
broader range of cognitive functions in a relative short amount of time. It also detects mild 
cognitive deterioration and has few ceiling effects. We investigated the clinical utility and 
diagnostic accuracy of the CAMCOG in patients with a recent stroke in a prospective study 
by comparing the CAMCOG with a final “gold standard” judgment of cognitive functioning.42 
Despite its length and multiplicity the CAMCOG appeared well administrable in an elderly 
stroke population, as has been confirmed by a study of Kwa et al.43 The CAMCOG was 
more sensitive and specific than the MMSE as a screening instrument for dementia in 
stroke patients. We found that apart from the CAMCOG score two other clinical variables 
independently improved the diagnostic accuracy. Patients with an intracerebral hemorrhage 
had approximately a three times larger risk to be demented after stroke in comparison with 
patients with a TIA or ischemic stroke, whereas patients with a left hemispheric stroke had 
a three times lower risk than patients with a right hemisphere stroke. According to our 
study results the CAMCOG is a feasible and accurate screening instrument for dementia in 
a stroke population, especially when type and site are taken into account.
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conclusIon
With the growing interest in dementing disorders the number of brief, and more or less 
standardized mental status tests has strongly increased. Most of these tests, however, 
are similar in many aspects. They are a subset from a larger itempool, that has been 
constructed with Alzheimer’s disease in mind. Not surprisingly most tests are sensitive to 
the cognitive deterioration compatible with Alzheimer’s disease, especially when age and 
education are taken into account. Brief screening tests are not suitable to differentiate 
between normal cognitive functioning en mild dementia. In patients with a recent stroke 
there are other demands to a dementia screening test. Since a stroke may cause both 
cortical and subcortical deficits, the clinical expression of poststroke dementia is different 
from that of Alzheimer’s disease. Due to the complexity and heterogeneity of the cognitive 
deficits a brief screening test is not informative. A screening test should contain items on 
more cognitive domains, and in addition to the items of brief mental tests this means that 
more attention should be paid tot subcortical deficits, like timed tasks and specific memory 
items. It may also be necessary to skip items like constructional abilities. The CAMCOG is 
somewhat longer and more comprehensive than regular screening tests, and seems to be 
an improvement, especially when other diagnostic factors are taken into account. However, 
instead of making adjustments to a test retrospectively, it is probably better to adjust the 
test itself. A screening instrument that is able to screen for dementia in a stroke population 
would be a valuable contribution to future research in vascular dementia.
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AbsTrAcT
Background. Most mental screening tests focus on the detection of cognitive deficits 
compatible with Alzheimer’s disease. Stroke patients who develop a dementia syndrome, 
however, constitute a more heterogeneous group with both cortical and subcortical 
disturbances. We assessed the diagnostic accuracy of the CAMCOG and MMSE for dementia, 
in patients with a recent stroke.
Methods. In patients aged 55 and over who were admitted in the Rotterdam Stroke Databank, 
cognitive functioning was assessed between three and nine months after the most recent 
stroke. The ”gold standard” diagnosis of dementia was compatible with the criteria of the 
DSM-III-R. Independently of the diagnostic procedure, the CAMCOG and MMSE score were 
obtained.
Results. Of 300 consecutive patients, 71 (23.7%) were demented. Sixteen severely demented 
patients were not testable and excluded. The CAMCOG and MMSE score were significantly 
related to dementia (both p<.0001) in a logistic regression model. Receiver Operating 
Characteristic (ROC) analysis showed that the CAMCOG was a more accurate screening 
instrument (area under the curve CAMCOG: 0.95 vs. area under the curve MMSE: 0.90). 
Two other clinical variables independently improved the diagnostic accuracy of the MMSE 
and CAMCOG: patients with a left hemispheric lesion had a lower (OR 0.3, 95% CI: 0.1–0.7), 
and patients with hemorrhagic stroke had a higher chance of being demented (OR 3; 
95% CI: 1–10). The effect of left hemispheric lesion as an independent diagnostic factor 
could not be explained by selection or its association with aphasia alone.
Conclusion. The CAMCOG is a feasible instrument in patients with a recent TIA or stroke. 
It is a more accurate screening tool for dementia than the MMSE, especially when type and 
site of stroke are taken into account.
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InTroducTIon
In patients with a recent stroke, it is important to assess cognitive deficits in a quick 
and convenient, but also reliable and accurate way. In the past, several mental status 
tests have been developed for this purpose, such as the Mini Mental State Examination 
(MMSE),1 Mental Status Questionnaire (MSQ),2 Short Portable Mental Status Questionnaire 
(SPMSQ),3 Cognitive Capacity Screening Examination (CCSE),4 Neurobehavioral Cognitive 
Status (NCSE),5 and the Short Blessed Test.6 Although these tests do not provide the same 
amount and type of information as a full neuropsychological examination, they may be 
used for selecting patients in whom such an extended neuropsychological examination is 
necessary. Most brief cognitive screening instruments have been developed for the detection 
of dementia of the Alzheimer type and focus on orientation, memory and higher cortical 
functions like aphasia, apraxia and agnosia. Aspects of cognitive functioning, like slowing of 
intellectual functioning, abstraction, retrieval and recognition, and visuo-perceptual abilities 
are less well measured. Stroke patients who develop dementia, however, may have deficits 
in any cognitive domain. The dementia syndrome may be classified as subcortical in some, 
and cortical in others. Previous studies in stroke populations also suggest that brief mental 
status tests are relatively insensitive to specific brain lesions or focal cognitive deficits.7 8 
Cognitive screening tasks predominantly contain verbally mediated items and therefore 
tend to exaggerate the extent of cognitive deficits in patients with left hemispheric lesions. 
Likewise, tests that emphasize verbal capacities may underestimate the consequences of 
right hemispheric lesions.9-11 The question is whether these tests are valid tools in stroke 
patients.
The CAMCOG is the cognitive and self-contained part of the Cambridge Examination for 
Mental Disorders of the Elderly (CAMDEX),12 a standardized instrument for the diagnosis 
and grading of dementia. The CAMCOG consists of 67 items with a maximum possible score 
of 107 and can be divided in several subscales: orientation, expressive and comprehensive 
language, memory (remote, recent and learning), attention, praxis, calculation, abstraction, 
and perception. All items of the MMSE are also incorporated in the CAMCOG. Although 
the CAMCOG was also originally designed to diagnose primary degenerative dementia it 
has an advantage over brief screening tests in that it covers a broader range of cognitive 
functions in a relative short amount of time. It also detects mild cognitive deterioration 
and has few ceiling effects.12 Studies of the CAMCOG have focused on the utility and 
validity of the complete CAMDEX.12-15 In most of these studies the CAMCOG cut-off point 
of 79/80 suggested by Roth et al. seemed satisfactory for discriminating between normal 
subjects and demented patients.12 Lindeboom et al. reviewed some psychometric properties 
of the CAMCOG and found that is was stable and reliable and differentiated well between 
normal cognitive functioning and mild cognitive impairment.16 So far, little is known about 
the diagnostic value of the CAMCOG in a stroke population. Somatic handicaps as well 
as cortical disturbances such as aphasia or neglect may have a negative influence on its 
accuracy.
In this study, we investigated the diagnostic value of the CAMCOG as a screening 
instrument for poststroke dementia in comparison with the MMSE. Furthermore, we assessed 
the role of other clinical factors, that could confound or modify the relation between the 
screening test results and the presence of dementia.
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subjecTs And meThods
Subjects
Patients were recruited from the Rotterdam Stroke Databank, a prospective registry of 
patients with a transient ischemic attack (TIA), ischemic stroke or primary intracerebral 
hemorrhage, admitted to the Department of Neurology of the University Hospital Rotterdam. 
From March 1, 1993 until January 15, 1996, all consecutive patients who met the criteria for 
enrolment in The Dutch Vascular Factors in Dementia Study were entered.17 Patients had to 
be 55 years or over, and had had a TIA with neurological signs on examination, an ischemic 
stroke or intracerebral hemorrhage. Patients were excluded when a reliable assessment of 
dementia could not be made because of aphasia (i.e. a score less than 3 on the Aphasia 
Severity Rating Scale from the Boston Diagnostic Aphasia Examination [BDAE]),18 severe 
sensory handicaps (e.g. deafness or blindness), persistent impairment in consciousness, 
severe psychiatric symptoms, or insufficient command of the Dutch language. Additional 
exclusions were a TIA without neurological signs, concomitant primary cerebral disorder 
or severe comorbidity with a short life expectancy. Informed consent was obtained from all 
patients or from close relatives in case of impaired judgment.
Procedure
The clinical characteristics of the patients at baseline were assessed shortly after admission 
to the hospital. We obtained detailed information about cardiovascular risk factors, stroke 
characteristics, and premorbid mental and physical status. In addition to a full neurological 
examination, ancillary investigations consisted of standardized blood tests, chest x-ray, 
computed tomographic scanning and/or magnetic resonance imaging of the brain, duplex 
scanning of the carotid arteries, and a cardiac analysis. Premorbid cognitive functioning was 
established by an interview with a close relative and the score on the Blessed dementia scale. 
Education was categorized by the number of years of schooling completed. Between three 
and nine months after stroke onset cognitive functioning was assessed by a neurologist, 
based on clinical observation, the information of a close informant and the score on the 
Blessed Dementia Scale. In case of any suspicion of cognitive decline patients were invited 
for an extensive neuropsychological examination. We used the Aphasia Severity Rating 
Scale of the BDAE to assess the presence and severity of aphasia. A score of 6 indicates no 
aphasia, and 5,4 and 3 mild to moderate aphasia. A psychiatric examination was carried out 
in all demented patients to assess the presence of depression.
The “gold standard” diagnosis of dementia was based on the results of an extensive 
neuropsychological examination, clinical presentation, and information from a close relative. 
Figure 1 represents the diagnostic procedure for dementia. The extensive neuropsychological 
examination was carried out in all patients in whom there was any suspicion of dementia 
or cognitive decline. If patients were not testable due to cognitive deficits or when 
they refused further co-operation, the extensive neuropsychological evaluation was not 
performed. In some patients only a limited number of tests could be administered. The 
extensive neuropsychological examination consisted of an intelligence test, either the 
shortened version of the Groninger Intelligence Test,19 a Dutch intelligence test, or when 
this was not administrable Raven’s Coloured Matrices,20 a non-verbal intelligence test. The 
shortened form of the Boston Naming Test (CERAD)21 was used to examine word finding 
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difficulties. Memory was evaluated with Word List Memory (CERAD),21 and the Rivermead 
Behavioural Memory Test.22 We used Digit Span forward and backward (WAIS)23 to assess 
the span of immediate verbal recall, but also as a measure for attentional capacity. Parts 
of the Trail Making Test,24 and the Stroop Color Word Test25 too were used to examine 
attention. Scores on verbal fluency (animals, occupations, letter B), Stroop Color Word Test 
part III,25 Trail Making Test B,24 served as indication for the level of executive functioning. 
Proverbs and similarities (WAIS)23 provided a measure for abstraction and verbal concept 
formation. Visuo-constructive ability was examined by copying the drawing of a circle, 
diamond, two overlapping rectangles and a cube (CERAD).21 Visual perception and 
spatial orientation were examined by Judgment of Line Orientation.26 Based on clinical 
presentation, information from a close relative, the score on the Blessed dementia scale, 
and the neuropsychological test results, a final judgment of cognitive functioning was made 
by a diagnostic panel consisting of two neurologists, a neuropsychologist and a trained 
physician. For the assessment of dementia, the criteria of the DSM-III-R were used.27 Further 
subclassification of dementia took place according to the research criteria of the NINDS-
AIREN international workshop.28
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Independently of the diagnostic procedure the MMSE and the Geriatric Mental Status 
(GMS),29 and the Dutch version of the cognitive and self contained part of the CAMDEX,30 31 
the CAMCOG, was administered in all patients.
sTATIsTIcAl AnAlysIs
For the comparison of the clinical characteristics of the demented and not-demented 
patients Student’s t-test and a chi-square test were used when appropriate. The relation 
between clinical characteristics and dementia was described by means of odds ratios with a 
95% confidence interval. The odds ratios for the dichotomous variables were estimated by 
contingency table analysis, and for the CAMCOG and MMSE by means of logistic regression. 
To determine the influence of other diagnostic information independently of the MMSE or 
CAMCOG score, multiple logistic regression was used. The diagnostic accuracy of the 
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CAMCOG and the MMSE, with and without adjustment for other diagnostic factors was 
compared by receiver operating characteristics (ROC) curves, by measuring the area under 
the curve. The statistical significance of the regression models was assessed by a standard 
likelihood ratio test, the fit was assessed by means of the Hosmer-Lemeshow chi square 
test, and by plotting observed and expected numbers of patients by deciles of the predicted 
probabilities. All statistical analyses were carried out using STATA software.32
resulTs
From the 825 patients that entered the Rotterdam Stroke Databank, 198 were younger than 
55 years of age, 122 died within three months after stroke onset, 42 had a TIA without 
any sign on neurological examination, 41 had severe aphasia, another 76 were excluded 
for various other reasons (e.g. moved out of the region, not speaking Dutch, short life 
expectancy due to other intracranial pathology), and 46 did not give informed consent 
(Figure 2). Of the remaining 300 patients who met the criteria for inclusion in The Dutch 
Table 1. Baseline characteristics of the study population
Total studygroup
(N=284)
not-demented
(N=229)
demented
(N=55)
Age * 69.2 (8.1) 68.2 (8.0) 73.0 (7.3)‡
years of education* 8.7 (3.1) 9.0 (3.0) 7.6 (2.9)§
female sex† 114 (40) 84 (37) 30 (55)||
cAmcog* 83.3 (14.1) 88.2 (8.7) 63.2 (14.1)‡
mmse* 25.4 (4.3) 26.7 (2.7) 19.9 (5.2) ‡
‘Pre-stroke’ blessed score >0† 26 (10) 6 (3) 20 (37) ‡
Type of stroke†
TIA
Ischemic infarction
Intracerebral hemorrhage
46 (16)
203 (71)
35 (12)
43 (19)
164 (71)
22 (10)
3 (5)
39 (71)
13 (24)§
site of stroke†
Right hemisphere
Left hemisphere
Infratentorial
133 (47)
116 (41)
35 (12)
104 (45)
100 (44)
25 (11)
29 (53)
16 (29)
10 (18)
dementia type†
Possible VaD
Probable VaD
Possible AD+CVD
5 (9)
35 (64)
15 (27)
Aphasia† 19 (7) 16 (7) 3 (5)
Apraxia† 9 (3) 3 (1) 6 (11)§
neglect† 15 (5) 4 (2) 11 (20)‡
hemianopia† 22 (8) 10 (4) 12 (22)‡
facial paralysis† 54 (19) 36 (16) 18 (33)§
Any arm paresis† 69 (24) 49 (21) 20 (36) ||
Any leg paresis† 64 (23) 44 (19) 20 (36)§
VaD = Vascular Dementia, AD+CVD = Alzheimer’s disease and cerebrovascular disease
* Values are means with standard deviations in parentheses
†Values are number of patients with (column) percentages in parentheses
‡ Demented patients significantly different from not-demented patients (p <0.001)
§ Demented patients significantly different from not-demented patients (p <0.01)
|| Demented patients significantly different from not-demented patients (p <0.05)
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Vascular Factors in Dementia Study, sixteen were excluded from the present study because 
the CAMCOG was not administrable due to severe dementia. The clinical characteristics of 
the 284 study patients are summarized in Table 1. The mean age was about 70 years and 
40% was female. One sixth of the patients had had a TIA, a little more than one tenth had 
had an intracerebral hemorrhage. Of the demented patients in our study population about 
one quarter was diagnosed as possible Alzheimer’s disease with cerebrovascular disease, the 
other demented patients were classified as possible or probable vascular dementia. Aphasia 
was present in 7% of all patients. Demented patients scored significantly lower on the 
CAMCOG, on average 25 points (95% CI: 22.1–27.9) than not-demented patients. Demented 
patients were on average 4.8 years older (95% CI: 2.5–7.1) and they were more often female. 
They had on average 1.4 years less education than not-demented patients (95% CI: 0.5–2.3). 
Neurological deficits such as the presence of apraxia, neglect, hemianopia, facial paralysis 
and paresis of arm or leg were associated with dementia, but aphasia was not. Table 2 gives 
the corresponding odds ratios with 95% confidence intervals for each factor by itself. In our 
study, each point increase in the CAMCOG score decreased the odds of being demented by 
0.83, and each point increase in the MMSE score decreased the odds of dementia by 0.64. 
Although the relative odds reduction per point is larger for the MMSE, the CAMCOG is by 
far the better test, because the range of possible scores is larger (30 vs. 107). ROC analysis 
shows that the CAMCOG was more accurate in screening for dementia than the MMSE 
(area under the ROC curve MMSE: 0.90 vs. area under the ROC curve CAMCOG: 0.95) 
Table 2. The relation between clinical characteristics and the presence of dementia
odds ratio 95% cI
Univariate analysis
cAmcog score 0.83 0.79 – 0.87*
mmse score 0.64 0.57 – 0.72*
Age 1.08 1.04 – 1.12*
female sex 2.1 1.1 - 3.7
years of education 0.83 0.73 - 0.93
TIA 0.25 0.08 - 0.77
left hemisphere 0.5 0.3 - 1.0
Intracerebral hemorrhage 2.9 1.4 - 6.2
Aphasia 0.8 0.2 – 2.6
Apraxia 9.7 2.6 – 36.8
neglect 11.2 3.9 – 32.4
Arm paresis 2.1 1.1 – 3.9
leg paresis 2.4 1.3 – 4.5
hemianopia 6.1 2.5 – 14.7
Multiple regression model
cAmcog score 0.83 0.79 – 0.87
left hemispheric lesion
Intracerebral hemorrhage
0.3
3.1
1.1 – 0.9
1.0 – 9.7
mmse score 0.63 0.56 – 0.71
left hemispheric lesion
Intracerebral hemorrhage
0.3
2.6
1.1 – 0.7
1.0 – 7.4
* estimated by logistic regression; odds ratios per unit increase
CI =confidence interval, MMSE = Mini Mental State Examination
The CAMCOG for dementia  screening in stroke patients 47
(Figure 3). We could improve the predictions by adding other diagnostic factors: patients 
with a left hemispheric lesion had a three times lower risk of dementia, independently of 
the CAMCOG or MMSE score, and patients with a hemorrhage lesion had an approximately 
three times higher risk of dementia, independently of test score. In univariate analyses, TIA 
was related to a reduced risk of dementia. In the multiple regression model, however, TIA 
was not significantly related to a reduced risk of dementia in our study population. Age, 
gender and education are known to be of influence on screening test scores, but showed 
no significant relation with both the presence of dementia and the CAMCOG score in our 
study. After adjusting for site and type of stroke, the area under the curve increased with 
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Figure 3. ROC curves to determine the diagnostic accuracy of the CAMCOG 
and the MMSE. 
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Figure 3. ROC curves to determine the diagnostic accuracy of the CAMCOG and the MMSE
Table 3. Observed and predicted number of demented patients, according to the four logistic regression models, by quintiles of the predicted 
probabilities
CAMCOG1 MMSE2 CAMCOG adjusted3 MMSE adjusted4
Hosmer-Lemeshow 
(χ2)
p=0.21 P=0.02 p=0.19 p=0.05
observed predicted observed predicted observed predicted observed predicted
 0  0.4  1  1.5  0  0.3  0  1.0
 1  1.4  2  4.7  0  0.7  0  2.3
 0  2.8  1  2.4  1  2.6  6  3.2
12  9.2 18 10.7 13  8.7 15 11.9
42 41.2 33 35.7 41 42.7 34 36.7
1 O= e 13.2 + (-0.19 × C)
2 O= e 9.2 + (-0.44 × M)
3 O= e 13.5 + (-0.19 × C) + (1.13 × H) + (-1.18 × L)
4 O= e 9.8 + (-0.46 × M) + (0.97 × H) + (-1.3 × L)
where O=odds of dementia, C=CAMCOG score, M=MMSE score, L=presence (1) or absence (0) of left hemispheric lesion, H=presence (1) or 
absence (0) of hemorrhagic stroke.
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0.01 in both curves. The predictions based on the MMSE were always less accurate than 
CAMCOG based predictions, even when they were adjusted for type and site of stroke. The 
predictions based on the CAMCOG with adjustment for the two diagnostic factors appeared 
to be the best, as the area under the ROC curve was largest (0.96). The CAMCOG had the 
best overall fit (Table 3). Figure 4 shows the relation between the risk of dementia and the 
CAMCOG score in our study, adjusted for type and site of stroke. The additional diagnostic 
factors have a maximum effect in the middle range of the CAMCOG scores. In our study 
about 45% of the patients have a CAMCOG score between 55 and 87. For example, the 
predicted probability of dementia in a patient with a CAMCOG score of 75 would be 30% 
in our study. Taking into account that this patient had a left ischemic stroke would lower 
the probability of dementia to 10%, while a patient with a right hemorrhage stroke and the 
same CAMCOG score is much more likely to be demented, with a probability of 60%.
dIscussIon
We investigated the diagnostic accuracy of the CAMCOG in patients with a recent stroke in 
a prospective study by comparing the CAMCOG with a final “gold standard” judgment of 
cognitive functioning. The CAMCOG was more sensitive and specific than the MMSE as a 
screening instrument for dementia in stroke patients. Despite its length and multiplicity, the 
CAMCOG appeared well administrable in an elderly stroke population. Of the 300 patients, 
the CAMCOG could be administered in 95% of the patients and the MMSE in 97%. The 
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Figure 4. The relation between the risk of dementia and the CAMCOG score, 
with adjustment for type and site of stroke, determined by logistic 
regression.  
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Figure 4. The relation between the risk of dementia and the CAMCOG score, with adjustment for type and site of stroke, determined by logistic 
regression
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experience with the CAMCOG in stroke populations is limited. Kwa et al. found that the 
CAMCOG was administrable in 88% of an ischemic stroke population, which also included 
patients younger than 55 years of age.33 Since their main interest was in the extent to which 
the CAMCOG is feasible in an ischemic stroke population, they included all aphasic patients 
and allowed adaptations in administration like the use of gestures. We excluded patients 
with a severe aphasia because differentiation between dementia and severe aphasia is very 
difficult and sometimes impossible even for experienced neuropsychologists who use a 
large test battery. The CAMCOG may be administrable in such patients but the score is 
meaningless because it remains unclear to what extent the total score is determined by the 
presence of dementia or by aphasia.
The finding that the CAMCOG is a more sensitive and specific screening instrument than 
the MMSE in an elderly stroke population is not surprising as the CAMCOG contains more 
items on memory, language and construction and allows a more differentiated judgment 
about these functions than the MMSE. Furthermore, the CAMCOG comprises items on more 
cognitive domains in comparison with the MMSE, by adding subtests abstraction, fluency 
and perceptual tasks. It is therefore a priori quite likely that the CAMCOG is more sensitive 
and specific than the MMSE in a heterogeneous group such as stroke patients. On the other 
hand, an addition of items by itself is not enough to increase sensitivity and specificity. 
Grace et al. performed a study in which the original MMSE was compared with a modified 
version, the 3MS.8 This modified version contains the items of the original MMSE but were 
given a different weight, and extra items were added, such as abstraction and fluency. 
In that study, the 3MS and MMSE had a similar overall classification accuracy, which was 
adequate for patients with left hemispheric strokes and poor for patients with right sided 
strokes. In our study, the CAMCOG score seemed to overestimate the risk of dementia in 
patients with a left hemispheric stroke compared to those with a right hemispheric stroke, 
which may indicate that the CAMCOG tends to overemphasize focal cognitive deficits in 
these patients.
Previous studies suggest that age and education are associated with dementia,34-37 and 
also with the performance on the CAMCOG.16 38 In our study, age and education had no 
additional diagnostic value in a multiple logistic regression model. One obvious explanation 
is that these factors are already accounted for in the CAMCOG score, as they are associated 
with dementia alone. We found that apart from the CAMCOG score, only type and site 
of stroke were useful in predicting the probability of dementia three months after stroke. 
Patients with an intracerebral hemorrhage had approximately a three times larger risk to be 
demented after stroke in comparison with patients with a TIA or ischemic stroke, whereas 
patients with a left hemispheric stroke had a three times lower risk than patients with a 
right hemisphere stroke. The finding that apraxia, mainly a consequence of left hemispheric 
lesions, was strongly associated with the presence of dementia in an univariate analysis, 
seems to be incongruent with this finding. The number of patients with apraxia, however, 
was small and therefore may have had little effect on the total group of patients with a left 
hemispheric stroke
Patients with a left hemispheric stroke were less likely to be demented three months 
after stroke, even after adjustment for other diagnostic factors, which is not in agreement 
with some other studies in which a left hemispheric stroke increases the risk of cognitive 
impairment or dementia.39-41 There are some explanations for our finding. First, we may have 
overestimated the role of mild and moderate aphasia in neuropsychological test scores and 
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therefore underestimated the extent of general cognitive decline. The proportion of aphasic 
patients in our study, however, was equal for demented and not-demented patients, also 
when we included the demented patients in which a CAMCOG was not administrable. 
Second, since patients with a severe aphasia were excluded because this prevented a 
reliable assessment of dementia, we excluded more massive left hemispheric strokes as 
opposed to massive right hemispheric strokes. In our study, however, patients with left 
hemisphere stroke did not differ from those with a right hemispheric stroke with respect to 
the presence of hemianopia, facial paresis, arm or leg paresis.
In conclusion, the CAMCOG is well administrable and it is an accurate screening tool 
for dementia in patients with a recent stroke. Our study results suggest that the CAMCOG 
has additional diagnostic value compared with the MMSE, especially when type and site 
of stroke are taken into account. A prospective study in a different, but comparable stroke 
population is needed to confirm our results.
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AbsTrAcT
Background and purpose. The CAMCOG is a feasible cognitive screening instrument for 
dementia in patients with a recent stroke. A major disadvantage of the CAMCOG, however, 
is its lengthy and relatively complex administration for screening purposes. We therefore 
developed the Rotterdam CAMCOG (R-CAMCOG), based on the original version. Our aim 
was to reduce the estimated administration time to 15 minutes or less, and to retain or 
perhaps even improve its diagnostic accuracy.
Methods. The itemscores on the CAMCOG of 300 consecutive stroke patients, after 
exclusion of patients with a severe aphasia or lowered consciousness level, who were 
entered in the Rotterdam Stroke Databank were analyzed. The diagnosis of dementia was 
made independently of the (R)-CAMCOG score, based on clinical examination and the 
neuropsychological test results. The R-CAMCOG was constructed in three steps. First, items 
with floor and ceiling effects were removed. Then, subscales with no additional diagnostic 
value were excluded. Finally, we removed items that did not contribute to the homogeneity 
of the subscales. The diagnostic accuracy of the R-CAMCOG and the original CAMCOG was 
determined by means of the area under the ROC curve.
Results. In the three steps, the number of items was reduced from 59 to 25, divided over the 
subscales orientation, memory (recent, remote and learning), perception and abstraction. 
The subscale orientation did not reach significance in a logistic regression model, but was 
included in the R-CAMCOG because of its high face validity in dementia screening. Internal 
validation with ROC analysis suggests that the R-CAMCOG and the CAMCOG are equally 
accurate in screening for poststroke dementia (area under the curve is 0.95 for both tests).
Conclusions. The R-CAMCOG has overcome the disadvantages of the original CAMCOG. It 
is a promising, short and easy-to-administer screening instrument for poststroke dementia. 
It seems to be sufficiently accurate for this purpose, but the test has yet to be validated in 
a separate, independent study.
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InTroducTIon
Cerebrovascular disease, in particular stroke, is a major cause of dementia.1-3 From both a 
clinical and research perspective it is therefore important to assess cognitive functioning 
after stroke. An extended neuropsychological examination, however, may not be necessary 
in all patients to establish a diagnosis and will be time-consuming and costly. On the other 
hand, brief mental status tests that have been developed to detect dementia compatible with 
Alzheimer’s disease, are often not sensitive enough to detect the specific and heterogeneous 
cognitive disturbances seen in poststroke dementia. Another drawback of these tests is that 
they heavily rely on language, often contain constructional items, and tend to disregard 
subcortical disturbances.4
The CAMCOG is the cognitive and self-contained part of the Cambridge Examination 
for Mental Disorders of the Elderly (CAMDEX)5 6 and was also primarily developed to 
detect cognitive disturbances compatible with Alzheimer’s disease. Previous studies 
have nevertheless shown that the CAMCOG is a feasible test for dementia in a stroke 
population.7 8 We studied its utility as a screening instrument for dementia in a stroke 
population and found that the CAMCOG was more accurate than the Mini Mental State 
Examination (MMSE). The diagnostic accuracy of the CAMCOG could even be improved 
when type and site of stroke were taken into account.8
A major disadvantage of the CAMCOG, however, is its lengthy administration time for 
the purpose of screening for dementia in a clinical setting, by a physician. We therefore 
adapted and modified the CAMCOG with two aims: to reduce its administration time 
from 25 minutes to approximately 15 minutes, and to retain or perhaps even improve its 
diagnostic accuracy. The results of the present study are based on analyses of the individual 
items of the CAMCOG performed in a cohort of 300 consecutive stroke patients entered in 
the Rotterdam Stroke Databank.
meThods
Patients
Patients were recruited from the Rotterdam Stroke Databank, a prospective registry of 
patients with transient ischemic attack (TIA), ischemic stroke or primary intracerebral 
hemorrhage, admitted to the Department of Neurology of the University Hospital Rotterdam. 
From March 1, 1993 until January 15, 1996, all consecutive patients who met the criteria for 
enrolment in The Dutch Vascular Factors in Dementia study were included in the present 
study.3 Patients had to be 55 years or over, and had had a TIA, an ischemic stroke or 
intracerebral hemorrhage. Patients were excluded when a reliable assessment of dementia 
could not be made due to aphasia (i.e. a score of <3 on the Aphasia Severity Rating Scale 
from the Boston Diagnostic Aphasia Examination [BDAE]),9 severe sensory handicaps (e.g. 
deaf or blind), lowered consciousness level, severe psychiatric symptoms, or insufficient 
command of the Dutch language. Additional reasons for exclusion were a concomitant 
primary cerebral disorder (e.g. Parkinson’s Disease) or severe comorbidity with a short life 
expectancy. Informed consent was obtained from all patients or from close relatives in case 
of impaired judgment. The local Medical Ethical Committee approved of the study.
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Procedure
During hospital admission, we obtained detailed information about cardiovascular risk 
factors, stroke characteristics, and premorbid mental and physical status. This procedure has 
been described in detail elsewhere.8 In addition to a full neurological examination, ancillary 
investigations consisted of standardized bloodtests, chest X-ray, computed tomographic 
scanning and/or magnetic resonance imaging of the brain, duplex scanning of the carotid 
arteries, and a cardiac analysis. Premorbid cognitive functioning was established by an 
interview with a close relative and the score on the Blessed dementia scale. Between 
three and nine months after stroke onset general and cognitive functioning was assessed, 
and blood and urinary samples were taken. A neurologist who also obtained information 
about actual cognitive functioning performed neurological examination. Based on clinical 
presentation, information from a close relative and the score on the Blessed dementia 
scale, judgment of cognitive functioning was made by behavioral neurologists and a 
neuropsychologist. We used the Aphasia Severity Rating Scale of the BDAE to assess the 
presence and severity of aphasia. A score of 6 indicates no aphasia, and 5,4 and 3 mild 
to moderate aphasia. Education was categorized by years of schooling completed. An 
extended neuropsychological examination was carried out in all patients who presented 
with cognitive complaints, or when a close relative mentioned a decline in cognitive 
functioning. An extended neuropsychological examination was also indicated when the 
investigators suspected a change in cognitive functioning, even when the patient or close 
relative had no complaints. Therefore, in all patients in whom there was any suspicion of 
dementia or cognitive decline an extended neuropsychological examination was carried 
out. When patients were not testable due to cognitive deficits or somatic handicaps or 
when they refused further co-operation, extended neuropsychological evaluation was 
not performed. In some patients only a limited number of tests could be administered. 
The extensive neuropsychological examination consisted of an intelligence test, either the 
shortened version of the Groninger Intelligence Test,10 a Dutch intelligence test, or when 
this was not administrable Raven’s Coloured Matrices,11 a non-verbal intelligence test. The 
shortened form of the Boston Naming Test (CERAD)12 was used to examine word-finding 
difficulties. Memory was evaluated with Word List Memory (CERAD),12 and the Rivermead 
Behavioural Memory Test.13 We used Digit Span forward and backward (WAIS)14 to assess 
the span of immediate verbal recall, but also as a measure for attentional capacity. Parts 
of the Trail Making Test,15 and the Stroop Color Word Test16 too were used to examine 
attention. Scores on verbal fluency (animals, occupations, letter B), Stroop Color Word Test 
part III,16 Trail Making Test B,15 served as indication for the level of executive functioning. 
Proverbs and similarities (WAIS)14 provided a measure for abstraction and verbal concept 
formation. Visuo-constructive ability was examined by copying the drawing of a circle, 
diamond, two overlapping rectangles and a cube (CERAD).12 Visual perception and spatial 
orientation were examined by Judgment of Line Orientation.17 Furthermore, in all patients 
the MMSE, the Geriatric Mental Status,18 and the Dutch version of the cognitive and self 
contained part of the CAMDEX, the CAMCOG, was administered.6 These tests did not act as 
a screening, but were administered to standardize the procedure as much as possible with 
the twin population-based part of the study, The Rotterdam Study.19 Although test behavior 
during the administration of the CAMCOG may have played a role in judgment of cognitive 
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functioning, the actual test scores were not taken in account. A psychiatric examination was 
performed in all demented patients to assess the presence of depression.
Based on clinical presentation, information from a close relative, the score on the 
Blessed dementia scale, and the neuropsychological test results, a final judgment of 
cognitive functioning was made by a diagnostic panel consisting of two neurologists, a 
neuropsychologist and a trained physician. For the assessment of dementia, the criteria of 
the DSM-III-R20 were used. In short, according to these criteria there has to be a demonstrable 
evidence of impairment in both short term and long term memory and at least disturbances 
in one other cognitive domain (i.e. impairment in abstract thinking, impaired judgment, 
other disturbances in higher cortical functioning, such as aphasia, agnosia, apraxia, or a 
personality change). The disturbances should be severe enough to interfere with daily 
functioning and occur not exclusively during the course of delirium.
Further differentiation of dementia took place according to the research criteria of the 
NINDS-AIREN International Workgroup for vascular dementia.21 Patients were diagnosed 
as suffering from a probable vascular dementia, possible vascular dementia, or possible 
Alzheimer’s’ Disease (AD) with cerebrovascular disease (CVD). This latter category was 
reserved for patients fulfilling the clinical criteria for possible AD and who also presented 
clinical or brain imaging evidence of relevant CVD. The severity of dementia was assessed 
by the Global Deterioration Scale22 and the Clinical Dementia Rating.23
Construction of the R-CAMCOG
The original CAMCOG contains 67 items of which 8 items are not included in the actual 
CAMCOG score. Five of these 8 items are included for assessment of the MMSE score 
and the other three items are optional, and do not affect the total CAMCOG score. The 
remaining 59 items, divided over 11 subscales, make up the CAMCOG score. Thirty-nine 
items are scored as right or wrong. Eleven items are gradual scores in which an answer can 
be wrong, right to a certain degree or completely right. The remaining 9 items are made 
up of more questions or commands and the ‘itemscore’ is the sum of the number of right 
answers. In line with the results of a previous study we assigned zero scores to all items 
that could not be administered due to upper extremity paresis.24 Items that were deemed 
inaccessible because of other factors, e.g. illiteracy or severe visual disturbances, were 
regarded as missing values, and were therefore not included in the statistical analyses.
The construction of the R-CAMCOG took place in several steps (Figure 1). The 
methodology and strategy was partly adapted from Van Straten et al., who adjusted the 
Sickness Impact Profile to a stroke population.25
In the first step we excluded the items which were considered to provide ceiling or 
floor effects. When more than 95% of the patients gave the right response to an item, we 
considered this a ceiling effect and when less than 5% of the patients gave the right answer 
to a question, this was considered a floor effect. In the second step we excluded the 
shortened subscales which had no additional diagnostic value. We carried out a multiple 
logistic regression analysis with the presence of dementia as dependent, and the shortened 
subscales as independent covariates. In a stepwise backward elimination procedure, the 
subscales with the highest diagnostic value were selected (p to enter 0.10, p to exit 0.15). 
In the final step we excluded items that did not contribute to the statistical coherence of 
a subscale. The mean inter-item correlation in each subscale, to be interpreted as internal 
consistency, was determined by means of Cronbach’s alpha.26
58
Ch
ap
te
r 5
We determined the (clinical) validity of the R-CAMCOG on the original study population. 
In the multiple logistic regression model the total CAMCOG score was correlated to the 
likelihood of dementia. The dependent factor was the presence of dementia and the 
independent factor was the total CAMCOG score. Receiver operating characteristic (ROC) 
analysis was performed to assess and compare the diagnostic accuracy of the two tests, by 
calculating the area under the curve.
All statistical analyses were carried out using Stata Software.27
resulTs
During the study period 825 patients entered the Rotterdam Stroke Databank. Of these 
patients, 198 were excluded because they were younger than 55 years of age, 122 had 
died and 42 patients had had a TIA with no neurological signs on examination. Of the 
remaining 463 patients, 41 had a severe aphasia (i.e. BDAE score less than 3) and 76 were 
Total number of items (subscales) 
in the original CAMCOG 
59(11)
Exclusion of the items with a floor or ceiling effect
Method: deleting items that are done wrong
or right by more than 5% of the patients
14(0)
Remaining number of
 items (subscales)
25(6)
Total number of items
(subscales) in the R-CAMCOG 
25(6)
Remaining number of 
items (subscales)
45(11)
Determining the internal consistency
Method: Cronbach’s α
Exclusion of subscales with no 
additional diagnostic value
Method: logistic regression analysis
with backward selection
20(5)
0(0)
Figure 1. The steps in the construction of the R-CAMCOG
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excluded for several other reasons (i.e. lowered level of consciousness, severe sensory 
handicaps, insufficient command of the Dutch language). Furthermore, 46 patients refused 
to participate in the study. From the 300 patients who met the criteria for inclusion in the 
Dutch Vascular Factors in Dementia Study, sixteen were excluded from the present study 
because the CAMCOG could not be administered due to severe dementia. All 300 patients, 
however, had a detailed dementia assessment. The baseline and demographic characteristics 
of the patients of the study population are shown in Table 1. The mean age was 70 years 
and 40% of the patients was female. About one sixth had had a TIA and approximately 10% 
had had an intracerebral hemorrhage. Right hemispheric stroke was slightly more common 
than left hemispheric stroke (47% vs. 41%). Approximately one quarter of the patients had 
any arm paresis and 7% had aphasia. Demented patients were on average 5 years older 
than not-demented patients and had had on average 1.4 years less education. Demented 
patients had more often had a right hemispheric stroke or an infratentorial stroke than 
not-demented patients. Whether this finding is related to the exclusion of severe aphasic 
patients has been discussed extensively in a previous study.8
In the first step of the construction of the R-CAMCOG, the exclusion of items with a ceiling 
effect, we excluded 14 items that were failed by less than 5% of our total study population. 
Most of the items that were removed were part of the subscale language, in particularly 
comprehension (Table 2). There were no items with a floor effect in the scores. The 
exclusion of items with a ceiling effect did not affect the number of subscales. In the second 
Table 1. Baseline characteristics of the study population
Total studygroup
(N=284)
not-demented
(N=229)
demented
(N=55)
Age * 69.2 (8.1) 68.2 (8.0) 73.0 (7.3)‡
years of education* 8.7 (3.1) 9.0 (3.0) 7.6 (2.9)§
female sex† 114 (40) 84 (37) 30 (55)||
cAmcog* 83.3 (14.1) 88.2 (8.7) 63.2 (14.1)‡
mmse* 25.4 (4.3) 26.7 (2.7) 19.9 (5.2) ‡
Type of stroke†
TIA
Cerebral infarction
Intracerebral hemorrhage
46 (16)
203 (71)
35 (12)
43 (19)
164 (71)
22 (10)
3 (5)
39 (71)
13 (24)§
site of stroke†
Right hemisphere
Left hemisphere
Infratentorial
133 (47)
116 (41)
35 (12)
104 (45)
100 (44)
25 (11)
29 (53)
16 (29)
10 (18)
dementia type†
Possible VaD
Probable VaD
Possible AD+CVD
5 (9)
35 (64)
15 (27)
Aphasia† 19 (7) 16 (7) 3 (5)
Apraxia† 9 (3) 3 (1) 6 (11)§
Any arm paresis† 69 (24) 49 (21) 20 (36) ||
VaD = Vascular Dementia, AD+CVD = Alzheimer’s disease and cerebrovascular disease
* Values are means with standard deviations between parentheses
†Values are number of patients with (column) percentages between parentheses
‡ Demented patients significantly different from not-demented patients (p <0.001)
§ Demented patients significantly different from not-demented patients (p <0.01)
|| Demented patients significantly different from not-demented patients (p <0.05)
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step we excluded the subscales with the lowest diagnostic value (Table 3). In the stepwise 
logistic regression with a backward selection on the 11 subscales, the shortened subscales 
orientation, language (comprehension and expression), attention, praxis, calculation were 
excluded, and abstraction, perception and all three memory subscales were retained.
All subscales showed a high average inter-item correlation and scale reliability coefficient, 
except for the subscale perception. This may be explained by the fact that this subscale 
is divided in two presumably distinct cognitive domains, tactile and visual perception. 
Therefore, the low inter-item correlation has no implications for the validity of the test and 
the subscale perception was included in the R-CAMCOG.
The shortened subscale orientation did not reach significance in the logistic regression 
model, but was included in the R-CAMCOG because it has high face validity in dementia 
screening.
The final version of the R-CAMCOG (appendix) contained 25 items divided over 6 
subscales: orientation, memory (recent, remote and learning), perception and abstraction. 
Table 2. Distribution of the items and subscales in the CAMCOG and the R-CAMCOG
CAMCOG Step 1 Step 2 Step 3 R-CAMCOG
Subscales Exclusion of items 
with ceiling effect
Exclusion of 
least relevant 
subscales
Internal 
consistency
Orientation 10  2  8  8  8
Language
– Comprehension  9  6  3  3
– Expression  8  2  6  6
Memory
– Learning  3  3  3  3
– Recent  4  1  3  3  3
– Remote  6  1  5  5  5
Concentration  2  2  2
Praxis  8  1  7  7
Calculation  2  2  2
Perception  3  1  2  2  2
Abstraction  4  4  4  4
Number of items 
(subscales)
59 (11) 14 (0) 45 (11) 20 (5) 25 (6) 0 (0) 25 (6)
Table 3. Relationship of CAMCOG subscales to the probability of dementia in a multiple regression model after backward elimination of the 
subscales
or 95% cI P
Orientation .99 .63 – 1.56 .97
Memory 
– Learning .46 .34 - .60 .00
– Recent .57 .32 - 1.03 .06
– Remote .77 .53 - 1.10 .15
Abstraction .74 .58 - .93 .01
Perception .64 .43 - .96 .03
OR: odds ratio, 95% CI: 95% confidence interval
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Some items, like naming of objects and writing an address, were included because they 
were required to test recall in the memory subscale. These items, nevertheless, were not 
included in the R-CAMCOG score.
We compared the diagnostic accuracy of the original CAMCOG and the R-CAMCOG 
on the original data that were used to construct the R-CAMCOG (Figure 2). ROC analysis 
suggests that the R-CAMCOG is equally accurate in screening for poststroke dementia 
(area under the ROC curve original CAMCOG and R-CAMCOG both: 95%). The sensitivity 
and specificity at the optimal cut-off point is equal for the CAMCOG and the R-CAMCOG 
(CAMCOG cut-off point 77: sensitivity 91%, specificity 88%; R-CAMCOG cut-off point 33: 
 
Figuur 2, hoofdstuk 5: A short screening instrument for poststroke dementia: the 
R-CAMCOG   
Figure 2. Receiver operating characteristic curves to determine the 
diagnostic accuracy of the original CAMCOG and the R-CAMCOG.  
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sensitivity: 91%, specificity: 90%). The diagnostic accuracy improved slightly when site and 
type of stroke were taken into account (area under the curve original CAMCOG and R-
CAMCOG both: 96%), similarly to the results of our previous study.
dIscussIon
In this study, we have developed a short and feasible screening instrument for poststroke 
dementia, the R-CAMCOG, based on the original CAMCOG. We analyzed the individual 
itemscores of the CAMCOG of 300 consecutive stroke patient of the Rotterdam Stroke 
Databank, aged 55 or over, without severe aphasia or sensory handicaps, and with a 
normal consciousness level. In three steps, the number of items was reduced from 59 to 25, 
divided over the subscales orientation, memory (recent, remote, learning), perception and 
abstraction. The administration time was reduced to approximately 10 minutes. Analyses 
in our original study population showed that the sensitivity and specificity were high and 
generally equal for the original CAMCOG and the R-CAMCOG.
To our knowledge, there are no dementia screening instruments that have been developed 
especially to screen for poststroke dementia. Some existing mental status tests, however, 
have been used and studied for this purpose. The MMSE is still a frequently used test in 
patients with a recent stroke, but has several disadvantages due to its emphasis on language 
and constructional items. We compared the MMSE to the CAMCOG in the Dutch Vascular 
Factors in Dementia Study and found that it was a less accurate screening instrument than 
the CAMCOG.8 Tatemichi et al. used the MMSE as a screening instrument and found that 
it can be of use when adjustments are made for the high rate of false positive scores, but 
an independent, prospective evaluation has not been carried out.28 Grace et al. performed 
a study in a geriatric stroke population, in which the original MMSE was compared with 
a modified version, the 3MS.29 In this study the 3MS was not better than the MMSE in 
diagnosing dementia. Thus, with its longer administration time, the 3MS had no clear 
advantage in clinical use in a geriatric stroke population.
Two other neuropsychological instruments that have been used in a stroke population, 
the Neurobehavioral Cognitive Status Examination30 and the Mattis Dementia Rating Scale,31 
are also classified as screening instruments. Considering the structure of these tests and the 
administration time, however, these tests are in fact microbatteries, and in our opinion do 
not serve the purpose of a dementia screening instrument
Previously, we found that the CAMCOG is a feasible screening instrument in a stroke 
population,8 which confirmed an earlier study.7 Nevertheless, the CAMCOG still has 
drawbacks, when it is applied in patients with a recent stroke. The CAMCOG contains items 
that seem inassessable in some stroke patients due to upper extremity paresis or aphasia; 
this will lead to missing values. Recently, we studied the significance of missing values due 
to upper extremity paresis and concluded that this does not affect the discriminatory ability 
of the constructional items of the CAMCOG.24 Another major drawback of the CAMCOG is 
its lengthy and relatively complex administration. In the R-CAMCOG these disadvantages 
have been overcome.
The domains and items of the R-CAMCOG overlap with other dementia screening 
instruments, such as the MMSE,32 3MS,33 and the short Blessed Test.34 All mental status 
tests contain orientation and memory questions. In our study, the subscale orientation 
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did not reach significance in a stepwise logistic regression analysis, but we included the 
orientation items because of their high face validity in clinical settings.4 35 Memory items 
are also represented in virtually all dementia screening instruments, but the extent to 
which memory is measured varies distinctively between the different tests. An advantage 
of the R-CAMCOG is that it emphasizes memory, by definition the most important feature 
of dementia. The R-CAMCOG, however, examines different aspects of memory and is 
therefore better able to detect subcortical features of memory disturbances as can be seen 
in poststroke dementia. In the R-CAMCOG, visual and verbal memory are tested, with a 
recall measure and a recognition condition to distinguish learning from retrieval deficits. 
Memory for remote and recent facts is also included in the R-CAMCOG.
Decreased abstraction is recognized as a possible feature of dementia, yet most mental 
status tests tend to neglect this ability. In the R-CAMCOG, the level of abstraction is measured 
by means of similarities.
The subscale perception of the R-CAMCOG includes tactile perception of coins and 
recognition of objects from an unusual view. Even though (visual)agnosia is a well-known 
feature of dementia, often included in diagnostic criteria, most mental screening tests do 
not test the presence of visual perceptual deficits other than in an object-naming task. 
In our experience, however, the item ‘unusual views’ (where objects to be named are 
photographed from an unusual angle), is generally more difficult and complex than merely 
naming objects, and may be better in screening for more subtle visual disturbances.
The subscales praxis and language were not included in the logistic regression model, 
even though these items seem by itself useful in screening for dementia. A possible 
explanation for this may be the redundancy of the items. A substantial number of items of 
the extensive subscale language was removed because of a floor effect in the first step of 
the construction of the R-CAMCOG. The low complexity of the language comprehension 
questions may be an explanation for this finding.
Executive functioning is assumed to play an important role in dementia, but is not tested 
in the R-CAMCOG. This may be largely inherent to the original CAMCOG, which contains 
hardly tasks that measure executive functioning. As yet, it is unknown whether the absence 
of executive tasks is a limitation of the R-CAMCOG. It seems plausible, however, that many 
of the tasks that measure executive functioning are too demanding for stroke patients in 
view of the somatic handicaps.
The final version of the R-CAMCOG shows overlap with other mental status tests with 
measures of orientation and memory, but lacks specific language items and constructional 
commands like drawing. Consequently, the R-CAMCOG can be used to screen for dementia 
without the disadvantage of confounding by the direct consequences of a stroke, like upper 
extremity paresis or mild aphasia. Clinical validation of the R-CAMCOG on the original 
data that were used to construct the R-CAMCOG showed a high sensitivity and specificity. 
External validation and assessment of reliability in a different series of stroke patients will 
be necessary to determine the value of the R-CAMCOG as a dementia screening instrument 
in patients with a recent stroke.
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APPendIx. The ITems of The r-cAmcog
Naming
Shoe Typewriter Scales Suitcase Barometer Lamp
Orientation
What day of the week is it? /1
What is the date today? Date Month Year /3
Can you tell me where we are now?
For instance in what province we are in. /1
What is the name of this town (city)? /1
What floor of the building are we on? /1
What is the name of this place? /1
Remote memory
Can you tell me when the First World War began? /1
Can you tell me when the Second World War began? /1
Who was the leader of the Russians in the Second World War? /1
What was Mae West famous for? /1
Who was the famous flyer whose son was kidnapped? /1
Recent memory
What is the name of the present Queen?
Who will follow her? /1
What is the name of the prime minister? /1
What has been in the news in the past week or two? /1
Recall
Can you tell me what were the objects in het coloured pictures I showed you a little 
while ago?
Shoe Typewriter Scales Suitcase Barometer Lamp /6
Recognition
Which of these did I show you before?
Shoe Typewriter Scales Suitcase Barometer Lamp /6
Writing an address
Write this name and address on the envelope
Mr. John Brown 42 West Street Bedford
Perception
I am going to place a coin into your hand and I want you to tell me what is is 
without looking at it.
Nickel Dime /2
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These are pictures of objects taken from unusual angles. Can you tell me what they 
are?
Spectacles Shoe Purse/Suitcase Cup&Saucer Telephone Pipe /6
Abstraction
In what way are an apple and a banana alike? /2
In what way are a shirt and a dress alike? /2
In what way are a table and a chair alike? /2
In what way are a plant and an animal alike? /2
Recall address
What was the name and address you wrote on the envelope a short time ago?
Mr. John Brown 42 West Street Bedford /5
Orientation     /8
Memory (recall and recognition)   /17
Remote memory     /5
Recent memory     /3
Abstraction     /8
Perception     /8
R-CAMCOG score     /49
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AbsTrAcT
Objectives. Specific screening-tests to detect poststroke dementia are lacking. We recently 
showed that an adaptation of the CAMCOG, the R-CAMCOG, had an excellent sensitivity and 
specificity in the detection of poststroke dementia. In this study, we externally validated the 
diagnostic accuracy of the R-CAMCOG in a new, representative cohort of stroke patients.
Methods. The R-CAMCOG and an extensive neuropsychological examination were 
administered, independently of each other, in 121 patients aged 55 and over with a stroke 
in the preceding 3 to 9 months. The gold standard for the diagnosis of dementia was based 
on the results of the extensive neuropsychological examination, clinical presentation, and 
information from a close relative, as well as on the DSM-IV criteria.
Results. Of the 121 patients, 35 were demented (29%) The diagnostic accuracy at the pre-
specified cut-off point of 33/34 was established through Receiver Operating Characteristics 
(ROC) analyses (sensitivity: 66%, specificity: 94%). At a cut-off point of 36/37 sensitivity 
would be 83% and specificity 78%.
Conclusion. The R-CAMCOG is a useful screening tool for poststroke dementia in a clinical 
setting.
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InTroducTIon
Until recently, no specific screening tests to detect poststroke dementia were available. This 
will lead to an increased risk of misclassification in screening procedures, as most screening 
tests are aimed at cortical disturbances, compatible with Alzheimer’s disease. We recently 
reported that the CAMCOG is suitable for screening in poststroke dementia,1 but that it has 
a major drawback, namely the relatively lengthy administration time of approximately 25 
minutes. We therefore made an adaptation of the CAMCOG, the Rotterdam CAMCOG, which 
is easy to administer and takes approximately 10 minutes.2 These aspects are important 
in stroke management, because of the high caseload: approximately one quarter of all 
hospitalized stroke patients will be demented.3-5 A first analysis of the diagnostic value of 
the R-CAMCOG on the same dataset that was used to develop the test suggested that the 
high sensitivity and specificity were preserved after adaptation.2 External validation and 
assessment of reliability in a different series of stroke patients is necessary to determine 
the value of the R-CAMCOG as a dementia-screening instrument in patients with a recent 
stroke. In this study, we prospectively assessed the diagnostic accuracy of the R-CAMCOG 
in a new, representative cohort of 121 stroke patients.
meThods
Patients
From October 2000 to July 2002 stroke patients from various centres in the region were 
included in the present study. Patients had to be 55 years or over, and had a transient 
ischemic attack (TIA) with neurological signs on examination, ischemic stroke or intracerebral 
hemorrhage, within the preceding 3 to 9 months. The stroke had to be confirmed by a 
neurologist and neuro-imaging had to be available. Patients were excluded when a reliable 
assessment of dementia could not be made because of aphasia (i.e. a score less than 3 on 
the Aphasia Severity Rating Scale from the Boston Diagnostic Aphasia Examination),6 severe 
sensory handicaps (e.g. deafness or blindness), persistent impairment in consciousness, 
severe psychiatric symptoms, or insufficient command of the Dutch language. Additional 
exclusions were a TIA without neurological signs on examination, concomitant primary 
cerebral disorder or severe comorbidity with a short life expectancy. Informed consent was 
obtained from all patients or from close relatives in case of impaired judgment. The local 
Medical Ethics Committee approved the study.
Procedure
In each centre, consecutive eligible patients or their family were asked to participate 
in the study. At inclusion, detailed information about cardiovascular risk factors, stroke 
characteristics, and premorbid status was obtained from the patient files. Premorbid 
cognitive functioning was assessed by means of an interview with a close relative and the 
score on the Blessed dementia scale7 to establish prestroke cognitive decline or dementia. 
Education was categorized by level: 1 indicates less than 6 years of primary education, 7 
indicates academic schooling.8 Between three and nine months after stroke onset two trained 
research assistants administered either the R-CAMCOG or an extended neuropsychological 
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examination, independently of each other. We used the same neuropsychological testbattery 
as in our previous study.1 The research assistant who administered the R-CAMCOG was 
unaware of the neuropsychological test results, and vice versa. The “gold standard” 
diagnosis of dementia was based on the results of the extensive neuropsychological 
examination, clinical presentation, and information from a close relative. When a patient 
was not able to perform a test due to a motor handicap, we used the results of the non-
motor counterpart(s).
In some patients not all tests could be administered due to cognitive disturbances and 
these patients were only included when a reliable judgment of cognitive functioning 
could be made. A final judgment of cognitive functioning was made by a diagnostic panel 
(neurologist and neuropsychologist). For the assessment of dementia, the criteria of the 
DSM-IV were used.9 Further subclassification of dementia was made according to the 
research criteria of the NINDS-AIREN international workshop,10 with possible Alzheimer’s 
disease (AD) with cerebrovascular disease as a possible diagnosis next to probable and 
possible vascular dementia (VAD).
sTATIsTIcs
For the comparison of the clinical characteristics of the demented and not-demented patients, 
Student’s t test and a chi-square test were used when appropriate. The diagnostic accuracy 
(sensitivity and specificity) of the R-CAMCOG was estimated with receiver operating 
characteristic (ROC) analyses at a pre-specified cut-off point of 33/34.2 All statistical analyses 
were carried out with Stata software.11
We estimated that a sample size of 150, with a prevalence of dementia of 20% would 
provide sufficiently accurate estimates of sensitivity and specificity (standard error of the 
mean: resp. 0.05 and 0.03). For logistic reasons, the total number of included patients 
was lower (121 vs. 150). Before analyzing the data we noted that, the standard error of 
our estimates would not be affected, because we had a higher frequency of patients with 
dementia than previously expected (29% vs. 20%). We could therefore expect that the 
precision of our estimates would not be affected by the smaller sample size.
resulTs
Of 130 patients considered eligible by the treating physician, nine had to be excluded: 
two patients were younger than 55, two patients had a history of psychiatric illness, in 
two (nursing-home) patients the diagnosis of stroke could not be confirmed, and in three 
patients informed consent was withdrawn after initial consent.
The baseline characteristics of the study-population are shown in Table 1. Mean age was 
70 years and approximately 40% was female. Demented patients were 7 years older than 
non-demented patients (p<0.001). There was no significant difference in level of education. 
None of the patients who suffered a TIA were demented. Six patients were demented before 
their most recent stroke (Alzheimer’s disease: 2, Vascular Dementia: 4). The total score, and 
subtestscores on the R-CAMCOG were significantly lower in the demented group.
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The diagnostic accuracy and test characteristics of the R-CAMCOG were determined at the 
pre-specified cut-off value of 33/34, which suggested the highest diagnostic accuracy in a 
previous study (Figure 1). The sensitivity at this cut-off value was 66% (95% CI: 50% – 82%), 
the specificity was 94% (95% CI: 89%–99%), with a positive predictive value of 82%.
dIscussIon
In this study, we confirmed the diagnostic accuracy of the R-CAMCOG in a representative 
stroke population. The findings of this study are different from our previous study in 
which the R-CAMCOG was developed. Not surprisingly, the sensitivity and specificity of the 
R-CAMCOG was higher in the previous study that provided the data used to construct the 
test. This is attributable to several types of optimism bias, that work during selection and 
evaluation of predictors.12 This in fact provided the rationale for carrying out this study.
Table 1. Demographic and clinical characteristics of the study population
demented
(N=35)
not-demented
(N=86)
Total
(N=121)
P
Age * (sd) 74.9 (8.8) 68.1 (8.3) 70 (9.0) <0.001
years of education* (sd)  8.9 (4.1)  9.6 (3.1) 9.4 (3.4) 0.17
level of education
Primary school
Vocational education
Secondary education 
17 (48%)
10 (29%)
 8 (23%)
27 (31%)
28 (33%)
31 (36%)
44 (37%)
38 (31%)
39 (32%)
0.18
female sex 13 (37%) 33 (38%) 46 (38%) 0.9
Type of stroke
TIA
Infarction
Intracerebral hemorrhage
 0 (0%)
28 (77%)
 8 (23%)
25 (29%)
50 (58%)
11 (13%)
25 (21%)
77 (63%)
19 (16%)
0.001
site of stroke
Infratentorial
Right hemisphere
Left hemisphere
 1 (3%)
23 (66%)
11 (31%)
 9 (11%)
39 (46%)
36 (43%)
10 (8%)
62 (52%)
47 (40%)
0.11
cT variables
Main findings (N=120)
Normal CT
Recent infarct only
Old infarct only
Single intracerebral hemorrhage
Multiple lesions 
 3 (9%)
15 (43%)
 4 (11%)
 7 (20%)
 6 (17%)
29 (34%)
27 (32%)
10 (12%)
 7 (8%)
12 (14%)
32 (27%)
42 (35%)
14 (12%)
14 (11%)
18 (15%)
0.05
Recent infarct type (N=58)
Large (endzone and/or large deep)
Lacune
17 (81%)
 4 (19%)
21 (57%)
16 (43%)
38 (66%)
20 (34%) 0.06
Leukoaraiosis (N=120)
Cerebral atrophy (N=120)
19 (54%)
 9 (26%)
23 (27%)
14 (16%)
42 (35%)
23 (19%)
0.004
0.24
r-cAmcog subscores (sd)
Orientation (max.=8)
Memory (max.=25)
Abstraction (max.=8)
Perception (max=8)
Total (max=49)
 5.5 (2.1)
14.1 (4.5)
 4.7 (2.2)
 4.5 (1.3)
28.8 (8.2)
 7.6 (0.6)
20.1 (2.7)
 6.3 (1.5)
 6.1 (1.3)
40.1 (4.1)
 7.0 (1.6)
18.4 (4.3)
 5.8 (1.9)
 5.7 (1.5)
36.8 (7.6.)
<0.001
<0.001
<0.001
<0.001
<0.001
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The clinical validity and usefulness of the R-CAMCOG depends on its accuracy and ease 
of use. In this respect, it is a limitation of this study that we could not directly compare the 
R-CAMCOG with the MMSE or other tests. At the pre-specified cut-off point, the sensitivity 
of the R-CAMCOG was estimated at 66% (95% CI: 50%–82%). The MMSE’s sensitivity was 
69% (95% CI: 57%–81%) at the accepted cut-off value of 23/24 in our previous study on 
vascular factors in dementia in a very similar stroke population. The R-CAMCOG, however, 
has a higher specificity (94% vs. 84%).1
A high specificity is of great importance, because the diagnostic work-up that follows 
in screen-positive patients will be time consuming for the patient and is expensive. The 
moderate sensitivity at the cut-off point of 33/34 may be a disadvantage in view of the 
recent developments of new and experimental treatments for poststroke dementia. For 
these purposes it may be a useful suggestion to set the cut-off value higher, as is frequently 
done with screening instruments in other studies. With a cut-off point of 36/37 the sensitivity 
increases considerably to 83% (95% CI: 71%–95%), while the specificity still is acceptable 
(78%; 95% CI: 70%–86%). Further testing of R-CAMCOG positive patients would yield a 
diagnosis of dementia in every second patient, while among R-CAMCOG negative patients 
1 in every 20 patients would be demented and “missed” initially.
For the present study, patients with a moderate or severe aphasia were excluded, because 
the R-CAMCOG was not considered suitable as a screening instrument in this subgroup. A 
screening tool for patients with moderate to severe aphasia would have additional value, 
but may not be easily realized.
Furthermore, a recent study of Graham et al.13 showed that executive functioning plays 
an important role in a particular subgroup of vascular dementia, e.g. subcortical vascular 
dementia. It remains unclear whether the lack of executive items in the R-CAMCOG is a 
drawback in screening for poststroke dementia. The clinical picture of stroke patients as 
Figuur 1, hoofdstuk 6: The diagnostic value of the Rotterdam-CAMCOG in 
poststroke dementia  
Figure 1. Receiver Operating Characteristic Curve to determine the 
diagnostic accuracy of the R-CAMCOG in a prospective study. 
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Figure 1. Receiver operating characteristic curve to determine the diagnostic accuracy of the R-CAMCOG in a prospective study
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well as the restraints due to the direct consequences of a stroke, like a hemi-paresis or mild 
aphasia may lay other demands on a screening instrument.
The impetus for developing a feasible and valid instrument to screen for poststroke 
dementia stems from the relative incompetence of the existing screening instruments for 
this purpose. Our study results suggest that the R-CAMCOG may be of limited use as a 
screening instrument in a large population, but is a useful instrument in screening for 
poststroke dementia in a clinical setting.
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AbsTrAcT
Background. The results of cognitive screening tests for poststroke dementia are usually 
interpreted dichotomously by means of a single cutpoint. This may lead either to redundant 
neuropsychological testing in subjects with obvious dementia and in false positive cases, 
or to unjustified reassurance of patients and relatives, all depending on the choice of 
the cutpoint. This calls for the use of two cutpoints. We examined whether the clinical 
usefulness of two cognitive screening tests, the MMSE and R-CAMCOG, could be enhanced 
by this approach.
Methods. We used data from two separate studies of poststroke dementia, with identical in- 
and exclusion criteria and procedure. We estimated the result-specific likelihood ratios from 
the MMSE and the R-CAMCOG from ROC curves, fitted with the Dorfman-Alf algorithm. 
We then defined cutpoints below and above which an additional neuropsychological 
examination would not contribute to the diagnosis, because the test result indicates a 
low, or high probability of poststroke dementia. These posterior probabilities were called 
threshold probabilities. Furthermore, we computed the proportion of patients in which an 
extended neuropsychological testing is necessary, because of diagnostic uncertainty.
Results. The area under the fitted ROC curve did not differ (MMSE: 0.895, R-CAMCOG: 
0.895). However, with a threshold probability of poststroke dementia of 5% and 95% 
the number of additional neuropsychological evaluations necessary for the diagnosis of 
poststroke dementia in a series of 1000 patients would be considerably lower when the 
R-CAMCOG is used instead of the MMSE (624 vs. 778). Threshold probabilities of 10% and 
90% would lead to a larger difference in number of neuropsychological examinations: 419 
vs. 592.
Conclusions. We provided a rational, probabilistic way to interpret screening test scores 
for poststroke dementia. The use of more than one cutpoint, depending on the intended 
level of diagnostic certainty, could lead to a reduction of redundant neuropsychological 
examinations.
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InTroducTIon
Cognitive screening tests can be useful in the diagnosis of dementia after stroke, but their 
accuracy and clinical value may be limited if the conclusion and subsequent diagnostic 
procedure are based on a single cutpoint. In that case, subjects with a score below a certain 
cutpoint are diagnosed as probably demented and are subjected to further testing, while 
subjects with a score above the chosen cutpoint are considered cognitively normal. This 
dichotomous interpretation of test results may lead either to redundant neuropsychological 
testing in subjects with obvious dementia and in false positive cases, or to unjustified 
reassurance of patients and relatives, all depending on the choice of the cutpoint.
In two earlier studies, we validated screening tests for poststroke dementia. In the hospital-
based part of the Dutch Vascular Factors in Dementia Study (DVFDS) we evaluated the 
diagnostic accuracy of the MMSE and the CAMCOG and found that both tests are feasible 
in a stroke population, with an advantage for the CAMCOG.1 Since an important drawback 
of the CAMCOG is its lengthy and relatively complex administration for screening purposes, 
we adapted and modified the CAMCOG to a shorter and easier-to-administer screening test, 
the R-CAMCOG.2 We recently assessed the accuracy of the R-CAMCOG.3 Although both 
the MMSE and the R-CAMCOG are feasible screening tests for poststroke dementia, their 
diagnostic accuracy is not optimal.
In the present study we analyzed the data on the MMSE and R-CAMCOG from two 
prospective, hospital-based studies on poststroke dementia. Instead of exclusively using 
sensitivity and specificity to determine a single cutpoint as a measure for the diagnostic 
accuracy, we determined two cutpoints, a lower below which a neuropsychological 
assessment is not informative because patients are evidently demented, and an upper 
above which additional testing is not required because patients are almost certainly 
cognitively normal. We used these parameters to compare the diagnostic accuracy and 
clinical usefulness of the MMSE and R-CAMCOG in a typical clinical setting.
PATIenTs And meThods
Patients
The present study is based on the results from two prospective studies on poststroke 
dementia. In the first study, the hospital based part of the Dutch Vascular Factors in Dementia 
Study (DVFDS), consecutive eligible patients were recruited from a prospective registry of 
patients with a TIA, ischemic stroke or primary intracerebral hemorrhage, admitted to the 
Department of Neurology of a University Hospital. From March 1, 1993 until January 15, 
1996, 284 patients were included.4
In the second study, in which the R-CAMCOG was externally validated, 121 consecutive 
eligible patients with a TIA, ischemic stroke or an intracerebral hemorrhage were included.3 
The distribution of patients per institution was matched to the distribution of discharge 
destination from a large regional stroke service in order to ensure the recruitment of patients 
in different settings with a wide range of stroke severity.
The in- and exclusion criteria were similar in both studies. Patients had to be 55 years 
or over, and had a TIA with neurological signs on examination, an ischemic stroke or 
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intracerebral hemorrhage. Patients were excluded when a reliable assessment of dementia 
could not be made due to aphasia (i.e. a score of <3 on the Aphasia Severity Rating Scale 
from the Boston Diagnostic Aphasia Examination [BDAE]),5 severe sensory handicaps (e.g. 
deaf or blind), lowered consciousness level, severe psychiatric symptoms, or insufficient 
command of the Dutch language. Additional reasons for exclusion were a concomitant 
primary cerebral disorder (e.g. Parkinson’s Disease) or severe comorbidity with a short life 
expectancy. Informed consent was obtained from all patients or from close relatives in case 
of impaired judgment. The local Medical Ethical Committee approved of both studies.
Procedure
For all patients, detailed information about cardiovascular risk factors, stroke characteristics, 
premorbid mental and physical status, and data on neuro-imaging were available, in 
identical format. The study procedures have been described in detail elsewhere.1 3
Premorbid cognitive functioning was established by an interview with a close relative 
and the score on the Blessed dementia scale. Between three and nine months after stroke 
onset cognitive functioning was assessed. We used the Aphasia Severity Rating Scale of the 
BDAE to assess the presence and severity of aphasia. A score of 6 indicates no aphasia, 
and 5, 4 and 3 mild to moderate aphasia. Education was categorized by years of schooling 
completed.
In the DVDFS, a judgment of present cognitive functioning was made by a neurologist, 
based on clinical presentation, information from a close relative and the score on the 
Blessed dementia scale.6 An extended neuropsychological examination was carried out in 
all patients who presented with cognitive complaints or when a close relative mentioned 
a decline in cognitive functioning. An extended neuropsychological examination was 
also indicated when the investigator suspected a change in cognitive functioning, even 
when the patient or close relative had no complaints. Therefore, in all patients in whom 
there was any suspicion of dementia or cognitive decline an extended neuropsychological 
examination was performed.
In the R-CAMCOG validation study, all patients underwent an extended neuropsychological 
examination. Two trained research assistants administered either the R-CAMCOG or a 
neuropsychological examination, independently of each other, between three and nine 
months after stroke onset. The research assistant who administered the R-CAMCOG was 
unaware of the neuropsychological test results, and vice versa.
The extensive neuropsychological examination consisted of an intelligence test, either the 
shortened version of the Groninger Intelligence Test,7 or when this was not administrable 
Raven’s Coloured Matrices8 a non-verbal intelligence test. The shortened form of the 
Boston Naming Test (CERAD)9 was used to examine word-finding difficulties. Memory 
was evaluated with Word List Memory (CERAD),9 and the Rivermead Behavioural Memory 
Test.10 We used Digit Span forward and backward (WAIS)11 to assess the span of immediate 
verbal recall, but also as a measure for attentional capacity. Parts of the Trail Making 
Test,12 and the Stroop Color Word Test13 too were used to examine attention. Scores on 
verbal fluency (animals, occupations, letter B), Stroop Color Word Test part III,13 Trail 
Making Test B,12 served as indication for the level of executive functioning. Proverbs and 
similarities (WAIS)11 provided a measure for abstraction and verbal concept formation. 
Visuo-constructive ability was examined by copying the drawing of a circle, diamond, two 
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overlapping rectangles and a cube (CERAD).9 Visual perception and spatial orientation 
were examined by Judgment of Line Orientation.14 In some patients only a limited number 
of tests could be administered due to cognitive disturbances, and these patients were only 
included when a reliable judgment of cognitive functioning could be made.
Furthermore, in both study groups, the MMSE or R-CAMCOG was administered 
independently of the validating neuropsychological examination.
Based on clinical presentation, information from a close relative, the score on the 
Blessed dementia scale, and the neuropsychological test results, a final judgment of 
cognitive functioning was made by a diagnostic panel consisting either of two neurologists, 
a neuropsychologist and a trained physician (DVFDS) or a vascular neurologist and a 
neuropsychologist. For the assessment of dementia, the criteria of the DSM-IV15 were 
used. Further differentiation of dementia took place according to the research criteria of 
the NINDS-AIREN International Workgroup for vascular dementia, with three possible 
diagnoses: probable vascular dementia, possible vascular dementia, and possible Alzheimer’s 
disease (AD) with cerebrovascular disease (CVD).16 The latter category was reserved for 
patients fulfilling the clinical criteria for possible AD and also presenting clinical or brain 
imaging evidence of relevant CVD. The severity of dementia was assessed by the Global 
Deterioration Scale17 and the Clinical Dementia Rating.18
sTATIsTIcAl AnAlysIs
For a comparison of the clinical characteristics of the demented and not-demented patients, 
Student’s t-test and a chi square test were used when appropriate.
The cumulative distribution of the two test scores was displayed as a receiver operating 
characteristic (ROC) curve, and the area under the curve was estimated using the method 
suggested by Hanley and McNeil.19 Next the ROC curves were fitted and parameterized, 
according to the method suggested by Dorfman and Alf,20 based upon the binormal model. 
This allowed us to obtain consistent estimates of the result-specific likelihood ratio. The 
result-specific likelihood ratio represents the likelihood of a certain (categorical) test result 
given the disease in question, divided by the likelihood of the test result given absence of 
the disease. On a smooth ROC curve it is equal to the tangent of the curve.21 This likelihood 
ratio for a single test value is considered the most appropriate parameter for evaluating 
diagnostic tests.22
For each test we defined cutpoints below and above which an additional neuropsychological 
examination would not be contributory to the diagnosis, because patients either have a 
very high, or a very low probability on dementia, e.g. are either obviously demented or 
can be considered cognitively normal. The lower cutpoint was chosen at 1%, 5%, or 10% 
of the intended threshold probability of poststroke dementia, and the upper cutpoint at 
99%, 95%, and 90% of the intended threshold probability. These posterior probabilities 
correspond to result-specific likelihood ratios of 0.03, 0.16, 0.33, 27, 54 and 273, assuming 
a prior probability of poststroke dementia of 25%. We computed the proportion of patients 
in the grey area, e.g. the proportion of patients in which an extended neuropsychological 
testing is necessary, because of diagnostic uncertainty.
The number of patients in this latter category depends on the discriminatory ability of the 
test, and on the closeness of the actual, result-specific likelihood ratios to the desired values: 
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the better the test, the smaller the number of patients requiring further neuropsychological 
testing. All statistical analyses were carried out with Stata statistical software.23
resulTs
The baseline characteristics of the patients from the two studies are shown in Table 1. 
Mean age was 70 years and approximately 40% was female. The mean number of years 
of education was similar in both studies. The proportion of demented patients was higher 
in the R-CAMCOG validation study (28.9% vs 19.4%), but patient groups did not differ in 
distribution of type and site of stroke. Demented patients were older and had less years of 
education than not-demented patients in both studies.
Figure 1 shows the ROC curves, fitted and parameterized with the Dorfman-Alf algorithm 
for both the MMSE and the R-CAMCOG. The areas under the curve were almost identical 
in size, estimated either from original data (MMSE: 0.900, SE 0.026; R-CAMCOG: 0.900, 
SE 0.034), or from the fitted curves (MMSE: 0.895, SE: 0.024; R-CAMCOG: 0.895, SE: 0.034). 
The result-specific likelihood ratios were estimated from the ROC curve, and nearest 
cutpoints were chosen for the MMSE and the R-CAMCOG. Tabel 2 shows lower and upper 
cutpoints for the MMSE and the R-CAMCOG to realize a certain diagnostic probability of 
poststroke dementia, assuming a prior odds for poststroke dementia of 1:3, e.g. a prior 
probability of 25%.
In an example with symmetrical threshold probabilities (5% and 95%) the nearest MMSE 
scores on the ROC curve are 28 and 13 (Table 2). The proportion of patients with an MMSE 
score at or above 28 is 0.198 and at or below 13 is 0.025. The nearest R-CAMCOG scores on 
the ROC curve for the cutpoints corresponding with threshold probabilities of 5% and 95% 
are 42 and 24, which leaves a proportion of patients with an R-CAMCOG score at or above 
42 of 0.288 and at or below 24 of 0.088.
Table 1. Clinical characteristics of both study populations.
dVfds
(n=284)
r-cAmcog
(n=121)
P
Age * 69.2.(8.1) 70.0 (9.0) 0.84
Poststroke dementia 55 (19.4%) 35 (28.9%) <0.05
female sex 114 (40%) 46 (38%) 0.69
years of education* 8.7 (3.1) 9.4 (3.4) 0.97
Type of stroke
TIA
Ischemic stroke
Intracerebral hemorrhage
46 (16.2%)
203 (71.5%)
35 (12.3%)
25 (20.7%)
77 (63.6%)
19 (15.7%)
0.29
site of stroke
Infratentorial
Right hemisphere
Left hemisphere
35 (12.3%)
133 (46.8%)
116 (40.9%)
10 (8.4%)
62 (52.1%)
47 (39.5%)
0.43
DVDFS: Dutch Vascular Factors in Dementia Study, R-CAMCOG: external validation study of the R-CAMCOG, TIA: transient ischemic attack
* mean with standard deviation between parentheses
The clinical usefulness of the MMSE and the R-CAMCOG 83
The number of patients who need an extended neuropsychological examination can be 
calculated by subtracting the number of patients with scores below the lower cutpoint and 
scores exceeding the upper cutpoint from the total population. In a hypothetical cohort of 
1000 patients the number of patients tested with the MMSE that are considered cognitively 
normal at a threshold probability of 5% is 198 (0.198 x 1000) and the number of patients 
that is obviously demented at a threshold probability of 95% is 25 (0.025 x 1000). The 
number of patients in the grey area, e.g. the number of patients in which the diagnosis is 
not certain, that needs an additional neuropsychological examination is 777 (1000 minus 
198+25).
Figuur 1, hoofdstuk 7: screening for poststroke dementia: clinical usefulness of 
the MMSE and the R-CAMCOG  
Figure 1. The ROC curves for the MMSE and the R-CAMCOG, 
parameterized and fitted with the Dorfman-Alf algorithm. 
 
 
 
Figure 1. The ROC curves for the MMSE and the R-CAMCOG, parameterized and fitted with the Dorfman-Alf algorithm
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A very high threshold probability (1% and 99%) results in large, almost equal numbers of 
additional neuropsychological examinations for both the MMSE (932) and the R-CAMCOG 
(939). When a lower diagnostic certainty is acceptable, e.g. 10% and 90% for the lower and 
upper cutpoint, 592 patients need an additional neuropsychological examination when 
screened with the MMSE and 419 patients when screened with the R-CAMCOG.
dIscussIon
In this study, we evaluated the diagnostic value of the MMSE and R-CAMCOG as screening 
instruments for poststroke dementia. Areas under the ROC curve were high, and identical 
indicating acceptable diagnostic accuracy. Instead of exclusively using sensitivity and 
specificity of a single cutpoint as measures for diagnostic accuracy, we determined the 
usefulness of more than one cutpoint, based on result-specific likelihood ratios, which were 
related to threshold probabilities of poststroke dementia above and below which further 
neuropsychological testing is not necessary. The first, the lower cutpoint that indicates the 
score below which a neuropsychological assessment is not informative, because patients 
are evidently demented, and the second, an upper cutpoint above which additional 
testing is not required because patients are likely to be cognitively normal. We found that 
depending on the intended level of threshold probability, a choice can be made between 
the R-CAMCOG and MMSE. The choice for a certain cutpoint need not only be determined 
by the result-specific likelihood ratios, but also by the ratio of losses incurred by making 
a false positive or a false negative diagnosis. Here, we implicitly assumed that these losses 
were equal.
A limitation of this study is that it is based on data of two cohorts of patients. We tried to 
overcome this drawback by estimating accuracy in the source populations, and transposing 
our estimates to a hypothetical population, thus ensuring that prior probability was identical 
for both tests. Furthermore, both studies were carried out by the same investigators, who 
applied a similar procedure and used the same definitions and variables. Small differences 
Table 2. Choice of cutpoints for R-CAMCOG and MMSE to realize a certain diagnostic probability of poststroke dementia, assuming a prior odds for 
poststroke dementia of 1:3. Next, nearest cutpoints are chosen, based on result-specific likelihood ratios estimated from the fitted ROC curves.
Threshold 
probability
Post 
odds
rs-lr mmse score P(mmse≥y) r-cAmcog score P(rc≥y)
1% 1:99 .03 29 0.053 46 0.015
5% 1:19 .16 28 0.198 42 0.288
10% 1:9 .33 27 0.362 38 0.489
Threshold 
probability
Post 
odds
rs-lr mmse P(mmse≤z) r-cAmcog score P(rc≤z)
90% 9:1  27 14 0.046 26 0.092
95% 19:1  57 13 0.025 24 0.088
99% 99:1 297  9 0.015 21 0.046
Rs-LR: result-specific likelihood ratio,
P(RC≥y): probability of an R-CAMCOG score at or above a certain value (y), P(MMSE ≥y): probability of an MMSE score at or above a certain 
value (y), P(RC≤z): probability of an R-CAMCOG score at or below a certain value (z), P(MMSE ≤z): probability of an MMSE score at or below a 
certain value (z)
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in patient selection between both studies, however, are inevitable. In the DVFDS, for 
instance, the number of prestroke dementia was considerably higher and more in line 
with the results of other studies in poststroke dementia than in the R-CAMCOG study (33% 
vs. 17%). Furthermore, only two patients in the R-CAMCOG study were diagnosed with 
AD+CVD, while 15 patients were diagnosed as such in the DVFDS study (6% vs. 27%). 
An explanation for the underrepresentation of prestroke cognitive decline and the small 
number of AD patients may be inherent to the selection of the patients. In the DVFDS, we 
included consecutive patients admitted to the department of neurology of our hospital, 
whereas the cohort in the R-CAMCOG study consisted of patients discharged from different 
hospitals. Although we tried to construct a representative cohort, we may have included 
a larger group with a relatively good outcome, and thus have disregarded patients with a 
pre-existent dementia or Alzheimer’s disease.
The MMSE clearly has some general advantages in screening for cognitive deterioration. 
It is widely used and internationally accepted, and has been evaluated in different patient 
groups, and different diseases. Furthermore, the MMSE is brief, and easy to administer. 
The strength of the R-CAMCOG in screening for poststroke dementia is that -although the 
overall diagnostic accuracy, as estimated from the area under the ROC curve, is similar- the 
distributions of scores are more finely categorized, thus allowing the clinician to use more 
precise cutpoints. This results in less overlap in scores between demented and not-demented 
patients than in the MMSE, with a smaller chance of misclassification. Furthermore, the 
R-CAMCOG has no floor- or ceiling effects, in contrast to the MMSE that has a known 
ceiling effect, especially in higher educated patients.
Our results suggest that in clinical settings, e.g. in smaller hospital based studies, the 
R-CAMCOG is more able to identify patients with or without poststroke dementia than the 
MMSE. This can be explained by the differences in test contents between the MMSE and the 
R-CAMCOG. The MMSE consists of 30 items with simple questions on several domains. The 
R-CAMCOG contains more items and emphasis lies on memory and these items account 
for almost half of the score. Moreover, memory is tested more comprehensively in the 
R-CAMCOG, with a retrieval and a recognition condition. As memory disturbances are still 
a core feature in dementia diagnosis, both in widely used diagnostic criteria as well as 
in our own clinical experience, the focus on memory items is an evident strength of the 
R-CAMCOG compared with the MMSE.
Furthermore, the MMSE contains tasks that require motor involvement, like drawing, 
writing and praxis. Such skills are frequently disturbed in stroke patients, due to pareses 
or neglect. The R-CAMCOG does not contain instructions with motor involvement that 
influence the score.
The MMSE has another drawback when it comes to screening for poststroke dementia. It 
contains questions regarding verbal expression or comprehension, that may cause problems 
for patients with aphasia, a common consequence of a stroke. In the R-CAMCOG, verbal 
responses are needed, but are not judged on linguistic aspects.
In our study, we used the NINDS/AIREN diagnostic criteria for vascular dementia. Over 
the years many studies have criticized these criteria, for instance for their lack of empirical 
evidence.24-26 Moreover, criticism was aimed at the diagnostic criteria for dementia for their 
emphasis on memory disturbances. Recent studies, though, found that disturbances in 
executive control functions are prominent and more severe in vascular dementia, while 
memory disturbances are relatively mild.27 28 Surprisingly, in the development of the 
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R-CAMCOG, executive function items did not contribute to its discriminatory ability, and a 
more prominent factor was memory. An explanation could be that most tests for executive 
function require a motor action (e.g. Trail Making Test part B, clock drawing) or need 
language involvement (e.g. verbal fluency, Stroop part III). Impairments in these two 
domains are frequently a direct consequence of a stroke.
Until now there is no perfect screening instrument for poststroke dementia. In this study, 
we provide an alternative way to interpret screening test scores, and a procedure that 
allows a more balanced diagnostic judgment. Due to its short and easy administration the 
MMSE may be more suitable in larger epidemiological studies, whereas the R-CAMCOG 
may be useful in smaller hospital-based studies and in clinical practice, where adequate 
selection of patients is of utmost importance.
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The aim of this thesis was to gain further insight in the diagnosis of dementia after a stroke. 
In the prospective hospital based part of the Dutch Vascular Factors in Dementia study 
(DVFDS),1 we investigated which clinical variables in the acute phase of stroke predicted 
poststroke dementia. The central topic of this thesis was to determine the usefulness of 
cognitive screening instruments in the diagnosis of poststroke dementia. We established 
the feasibility and diagnostic accuracy of existing screening instruments, the MMSE and the 
CAMCOG, and of a newly developed screening instrument, the R-CAMCOG.
In this chapter, I will summarize the main findings, followed by some methodological 
considerations. The value and use of screening instruments in the diagnosis of poststroke 
dementia and the diagnosis of dementia after a stroke itself will be discussed. I will end 
with conclusions and suggestions for future research.
mAIn fIndIngs
In line with the findings of other hospital based studies in stroke patients, we found that 
approximately one quarter of the stroke patients were demented three to nine months 
after the stroke, and about one fifth when patients with a moderate or severe pre-existent 
dementia were excluded.
Easily obtainable clinical variables in the acute phase that were included in a prediction 
model for poststroke dementia were age, level of education, female sex, mean arterial 
blood pressure, presence of white matter lesions, neglect, hemorrhagic stroke and atrial 
fibrillation.
The MMSE and the CAMCOG both proved feasible screening instruments for dementia 
in a stroke population. We encountered no severe problems in the administration of the 
two tests and there were relatively few missing values. The CAMCOG, however, came 
out as the better test, with a higher diagnostic accuracy. The diagnostic accuracy of both 
tests could be improved by taking type and site of stroke into account. Patients with a 
hemorrhagic stroke had a threefold higher risk of dementia compared with patients with 
a TIA or ischemic stroke, whereas the risk of dementia was lower in patients with a left 
hemispheric stroke.
The relatively lengthy and complex administration makes the CAMCOG less suitable 
for screening purposes. We therefore developed the R-CAMCOG, based on the original 
CAMCOG. Internal validation suggested that the R-CAMCOG and the CAMCOG were 
equally accurate in screening for poststroke dementia in the target population, with an 
excellent diagnostic accuracy.
External validation in a new comparable stroke population was performed in the R-
CAMCOG study. In this study, the R-CAMCOG had a moderate sensitivity and an excellent 
specificity at a prespecified cut-off point of 33/34. Finally, we compared the clinical 
usefulness of the R-CAMCOG and the MMSE in screening for poststroke dementia, by 
determining cutpoints at different threshold probabilities below and above which an 
extended neuropsychological examination is presumed to have little or no additional value 
in the diagnosis of poststroke dementia. Based on these data we were able to calculate the 
proportion of patients in whom diagnostic uncertainty requires extended neuropsychological 
testing. Although the overall diagnostic accuracy, as estimated from the area under the ROC 
curve, was similar for both the MMSE and the R-CAMCOG, the distributions of scores of 
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the R-CAMCOG were more finely categorized, thus allowing the clinician to use more 
precise cutpoints. Furthermore, in the R-CAMCOG the distribution of scores in demented 
and not-demented patients showed less overlap than in the MMSE, with a smaller chance 
of misclassification. Therefore, the R-CAMCOG seems to be the better screening test in 
smaller, hospital based studies, where adequate selection of patients is most important. 
Due to its short and easy administration the MMSE seems to have an advantage over the 
R-CAMCOG in large epidemiological studies, where different requirements on diagnostic 
accuracy apply.
meThodologIcAl consIderATIons
Methodological issues specific for each study have been described extensively in the 
separate chapters. Here, I will elaborate on some general specific methodological aspects 
of our studies.
Selection bias
Selection bias results from the selective exclusion of patients with the same disease in 
whom a different association may exist between a determinant and an outcome variable in 
comparison with those who participate in the study. The in- and exclusion criteria in our 
studies may have caused selection bias, especially the exclusion of patients with a moderate 
or severe aphasia. We excluded patients with a moderate or severe aphasia because this 
could confound neuropsychological test results, which may not only be a factor of influence 
in verbal tests, but also in tests with an instruction that rely on verbal support or tests that 
make use of symbols. Most other hospital-based studies of poststroke dementia have also 
excluded patients with moderate to severe aphasia and it was also an exclusion criterion in 
the research criteria for vascular dementia of the NINDS-AIREN International Workshop.2-4 
Consequently, cognitive decline after left hemispheric stroke may be underestimated.
Recruitment bias
In the hospital-based part of the DVFDS we followed another inclusion strategy than in the 
R-CAMCOG study. In the former, we included all consecutive patients who were admitted 
to a single university hospital and fulfilled the in- and exclusion criteria. In the R-CAMCOG 
study, we attempted to construct a representative stroke population, based on the discharge 
location of the participating hospitals in a regional stroke service. The reason for this was 
that we wanted to ensure the recruitment of patients with a wide range of stroke severity 
in order to establish the discriminatory value of the R-CAMCOG. In the R-CAMCOG study, 
the prevalence of dementia was somewhat higher than in the study in which we evaluated 
the CAMCOG (29% vs 19%), and comparable to other hospital based studies with the same 
design.3 5-7 On the other hand, the proportion of demented patients with a pre-existent 
dementia was lower in the R-CAMCOG study (17% vs. 33%). The low prevalence of pre-
existent dementia and Alzheimer’s disease probably results from a recruitment bias. The 
differences in dementia prevalence between the study populations was not considered a 
methodological problem in the external validation of the R-CAMCOG, because we wanted 
to establish the discriminatory ability of the test. In the study in which we compared the 
clinical usefulness of the R-CAMCOG and the MMSE, however, we needed to address this 
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problem. As I describe in chapter 7 we tried to overcome this drawback by estimating 
accuracy in the source population, and transposing our estimates to a hypothetical 
population, thus ensuring that prior probability was identical for both tests. Furthermore, 
both studies were performed by the same investigators, followed a similar procedure and 
used the same definitions and variables. Small differences in patient selection between both 
studies however, are inevitable.
Confounding factors in neuropsychological testing
The “gold standard” diagnosis of dementia in our studies was based on clinical presentation, 
information from a close relative, and for the major part on the results of an extensive 
neuropsychological examination.
Confounding is a frequent and inevitable phenomenon in neuropsychological practice. 
Statistical confounding can occur when an extraneous factor is associated both with the 
studied determinant and the outcome variable, which may obscure a relation. Age, sex, level 
of education or intelligence are potential confounders in studies of cognitive functioning. In 
neuropsychological practice the effect of these general confounders can be minimized by 
the use of adjusted norms. Neuropsychological performance can also be influenced by other 
factors that confound the test results. Some general confounding factors are common in all 
patients, like motivational problems, fear of failure, aggravation, fatigue, pain, emotional 
preoccupations, stress, mood disturbances, distractibility, and cultural background. These 
factors may influence neuropsychological test performance, and the neuropsychologist has 
to weigh the contribution of the confounders to the neuropsychological test results. Other 
confounding variables are found in specific diseases or patient groups. In stroke patients, 
specific confounding factors have to be taken into account in neuropsychological testing. 
Unlike primary degenerative dementia syndromes like Alzheimer’s disease or frontotemporal 
dementia, performance in stroke patients may be hampered by the direct consequences of 
a stroke, such as hemiparesis, aphasia or neglect.
A common consequence of a stroke is a hemiparesis. Obviously, a paretic arm, especially 
the dominant, influences performance on constructional tasks such as drawing, but also 
on paper-and-pencil tasks with a timed condition, as for instance the Trail Making Test. 
This may cause invalid test results or missing values. In our studies, there were relatively 
few missing values in the screening tests, but we found that missing values due to an arm 
paresis did not occur randomly in stroke patients. Items were more frequently scored as 
inassessable in demented than in not-demented patients. The presence or absence of an 
arm paresis, however, did not affect the relationship between dementia and constructional 
items, nor did it influence the discriminatory ability of the constructional items. We conclude 
that missing values in constructive items due to an arm paresis can be discarded and safely 
replaced by zero scores. An explanation for this may be that not-demented patients in 
general are better able to compensate for their paresis than demented patients.
Previously, I discussed the possible selection bias due to the exclusion of patients 
with a moderate or severe aphasia. The inclusion of patients with a mild or moderate 
aphasia, however, may also have influenced the neuropsychological test results. We 
may have overestimated the role of mild and moderate aphasia in neuropsychological 
test performance and hence underestimated the extent of general cognitive decline. The 
proportion of patients with a mild aphasia in the DVFDS, however, was equal among 
demented and not-demented patients, and thus confounding, if any, is probably minimal.
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Patients with hemi-inattention or -neglect were entered in our studies if they met the in- 
and exclusion criteria. Similar to aphasia, neglect may both directly and indirectly influence 
the neuropsychological test results. In neglect, visual and attentional problems may be 
expected and take a prominent place, but the impact of neglect is often more general and can 
be reflected in the performance on any task. Furthermore, neglect is often a consequence of 
right hemispheric stroke that is frequently accompanied by diminished insight in one’s own 
performance, often reflected by an overestimation of cognitive functioning and denying 
or minimizing cognitive deficits. This may lead to a biased judgment of the investigator. 
Finally, neglect may be less manifest in a clinical setting than (even mild) aphasia. Aphasia 
is a well-known consequence of a stroke and easier recognized during an interview than 
neglect, either sensory or visual.
To minimize the effect of confounding factors in neuropsychological testing, we 
administered more than one test for a cognitive domain, e.g. a verbal and a predominantly 
non-verbal memory test, or tests for executive functioning in timed and not-timed 
conditions. Furthermore, all neuropsychological tests were either administered by a 
clinical neuropsychologist or by trained test assistants under strict supervision of a clinical 
neuropsychologist.
screenIng InsTrumenTs In PosTsTroKe demenTIA
At the time we started our studies there were no dementia screening instruments specifically 
designed for vascular dementia or poststroke dementia. Systematic research of the clinical 
determinants of dementia after stroke had only just started, and was focused on the diagnosis 
and features of poststroke dementia, and not on the instrument by which the diagnosis 
was made. In the previous chapters, I have described the advantages and drawbacks of 
screening instruments. Due to the heterogeneity of the cognitive profile in dementia after 
stroke and possible confounding factors, we expected that the MMSE would not meet the 
requirements of a useful screening test for dementia after a stroke. We therefore decided 
to study the feasibility and diagnostic accuracy of the CAMCOG in screening for poststroke 
dementia. Despite the fact that the CAMCOG was also originally designed to diagnose 
primary degenerative dementia, we hypothesized that it would provide a more differentiated 
picture of cognitive functioning, and hence be a more accurate screening instrument in a 
stroke population. We confirmed this hypothesis in the DVFDS, but should have foreseen 
that the CAMCOG would not become a useful screening test in a clinical setting, simply 
because the CAMCOG does not fulfill a major demand of a cognitive screening instrument, 
namely a brief and easy administration.
Next to a high diagnostic accuracy, a short and easy administration was one of the main 
requirements for the R-CAMCOG. In line with the concepts of vascular dementia at the 
time, we envisaged a prominent role for tasks that measure executive functioning in the R-
CAMCOG. The R-CAMCOG, however, does not contain executive tasks, which reflects the 
fact that the original CAMCOG contains only a few tasks that measure executive functioning 
to some extent, such as clock drawing and wordfluency. These subtests, however, had no 
discriminatory ability in our analyses. One explanation may be that these tasks require 
either a motor action or language involvement, two domains that are frequently affected 
by a stroke, and therefore have minimal discriminatory ability. Another explanation may be 
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that disturbances in executive functioning play a less prominent role in poststroke dementia 
than previously assumed. Several studies have tried to determine a unitary cognitive profile 
of vascular dementia, and have frequently concluded that executive functioning deficits 
are more prominent and memory deficits are relatively mild in vascular dementia.8-10 There 
are, however, several potential limitations of these comparative studies.10 The uncertainty 
regarding the validity of the vascular dementia concept, the use of different diagnostic 
criteria, and possible circular reasoning owing to the dementia criteria used may obscure or 
emphasize differences. Furthermore, methodological shortcomings in the design of many 
studies, such as a selection bias regarding patients with relative mild cognitive decline and 
different severity of cognitive decline among patient groups, obscures the separate cognitive 
profiles. As I will discuss in the next section, the diagnostic criteria for vascular dementia 
are subject to considerable debate. Perhaps executive functioning deficits play a dominant 
role in some distinct forms of dementia after a stroke but not in others. Patients with 
dementia and lacunar infarcts and/or white matter lesions, recently coined as subcortical 
vascular dementia, predominantly have executive function deficits,11 12 analogous to other 
subcortical dementia syndromes. In contrast, the clinical picture of patients with large 
cortical infarcts may be dominated by cortical deficits and neurological disturbances.
The central cognitive function tested in the R-CAMCOG is memory. An advantage of the 
R-CAMCOG is that memory is tested more comprehensively than in most brief screening 
instruments, with both a recall and a recognition condition. A differentiation between an 
attentional problem, which is often the underlying cause of a low or subnormal score on the 
memory items of the MMSE, and a memory problem can easier be made. Furthermore, the 
larger number of items in the R-CAMCOG prevents ceiling effects, which can be important 
in poststroke dementia, because memory disturbances may vary from mild to severe.
A major advantage of the R-CAMCOG in screening for dementia in stroke patients, 
however, is that it minimizes confounding effects from the direct consequences of a stroke. 
Although the R-CAMCOG contains questions that need a verbal or motor response, they are 
not judged on linguistic or constructional aspects.
The dIAgnosIs of demenTIA In sTroKe PATIenTs
Stroke has been recognized as a cause of dementia since Hachinski proposed the concept of 
multi-infarct dementia. On the basis of a correlation between the presence of dementia with 
volume of brain tissue lost to infarction,13 Hachinski introduced the first set of diagnostic 
criteria for vascular dementia: the Hachinski Ischemic Score.14
In the early nineties the research criteria for vascular dementia have been designed by the 
NINDS-AIREN International Workshop.4 These criteria have been applied in several hospital 
based studies of dementia after a stroke and were also used in our studies. 6 15-18 Over 
the years many researchers have criticized these and other research criteria, for instance 
for their lack of empirical evidence. Criticism was also directed at the general diagnostic 
criteria for dementia that are based on the concept of Alzheimer’s disease with emphasis on 
memory disturbances. Another target for criticism was the fact that the criteria relied heavily 
on the multi-infarct model with stroke as the cause for dementia.
The results of studies in stroke populations increased the awareness that several 
mechanisms may underlie dementia after a stroke.19 Dementia may be a direct consequence 
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of the vascular lesions in the brain, but may also be due to sofar asymptomatic Alzheimer 
pathology or white matter lesions. Furthermore, a summation of infarcts in the brain, white 
matter lesions and Alzheimer pathology may lead to dementia, even when each type of 
lesion in itself is not severe enough to induce dementia. The term poststroke dementia is 
purely descriptive, has no inherent pathophysiological meaning and includes all possible 
mechanisms of dementia.
An advantage of this term and its implied multifactorial approach is that it enables 
research in the vascular factors that play a role in different forms of dementia, which may 
provide insight in pathophysiological mechanisms. A drawback is that it includes dementia 
with different cognitive profiles, which may obscure the clinical picture.
A recent published consensus statement proposes to replace the term vascular dementia 
by vascular cognitive impairment.20 This new clinical entity comprises hereditary vascular 
dementia’s, multi-infarct dementia, poststroke dementia, subcortical ischemic vascular 
dementia, mild cognitive impairment, but also degenerative dementia syndromes. The 
common feature is that vascular pathology either causes or substantially contributes to the 
cognitive impairment. Despite the progress made on the field of vascular dementia, the 
developments are evolutionary rather than revolutionary. From a clinical point of view, a 
useful recommendation in the consensus statement is the urge to distinguish homogeneous 
subtypes of vascular cognitive impairment, and to develop new diagnostic criteria for 
vascular cognitive impairment.
conclusIons And fuTure dIrecTIons
We performed our studies at a time of changing ideas and concepts regarding vascular 
dementia and dementia after stroke. Despite the progress made on possible mechanisms, the 
redefinition of diagnostic criteria and attempts on subtyping vascular dementia syndromes, 
the diagnosis of poststroke dementia is complex and time consuming. This is largely due 
to the heterogeneous nature of its clinical picture and the many confounding factors that 
may hamper a judgment of cognitive functioning. In this thesis, I have provided clues for 
identifying patients at risk for dementia in the acute phase of stroke by means of easily 
obtainable clinical variables. Furthermore, the R-CAMCOG proved a feasible and useful 
screening instrument in the diagnosis of dementia three to nine months after a stroke. 
Especially its excellent specificity makes the R-CAMCOG suitable for smaller clinical studies 
or therapeutic trials in which adequate selection of potential candidates is desired.
In view of the high incidence of dementia after a stroke and the advances in the 
development of therapeutic strategies, it is important to early select stroke patients with 
a high risk of dementia for further diagnostic work up, in order to optimize management 
and care of both patients and relatives. For this purpose, a cognitive screening instrument 
developed for administration in the acute phase of a stroke with a high predictive value 
for poststroke dementia would be a valuable contribution. However, the feasibility, and 
reliability of evaluation of cognition in the acute phase of stroke may raise problems. 
Fluctuating level of consciousness, general malaise, stress, and fatigue are common features 
within the first days after stroke that likely influence performance on neuropsychological 
tests. Moreover, a substantial proportion of the stroke patients in the acute phase may 
be too ill to be tested. The clinical heterogeneity of the ‘umbrella’ concept of poststroke 
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dementia hampers the quality of patient selection, in the acute as well as the chronic phase 
after a stroke. Future research should therefore be aimed at gaining further insight in more 
homogeneous subtypes of cognitive impairment related to stroke. Recently, diagnostic 
criteria for subcortical vascular ischemic dementia have been proposed.12 Other potential 
subgroups may be cognitive impairment due to multiple cortical infarcts or the specific 
cognitive profiles after a strategic infarct. The value of screening instruments, including the 
MMSE and the R-CAMCOG, needs to be re-evaluated in these specific subgroups of stroke 
patients.
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summAry
A stroke often results not only in physical disability, but also in cognitive impairment or 
even dementia. Between 10 and 40% of patients with a recent stroke becomes demented. 
The diagnosis of dementia after a stroke is difficult because of very heterogeneous cognitive 
disturbances, that may be characterized as cortical or subcortical, or a combination of the 
two. Furthermore, judgment of cognitive functioning may be hampered by the somatic 
symptoms that often accompany a stroke.
In clinical practice, cognitive screening instruments are important, both to select patients 
who need further neuropsychological testing and as a diagnostic tool in patients with 
obvious dementia. Most existing screening instruments used in a clinical setting, however, 
are developed to detect dementia compatible with Alzheimer’s disease and their value in 
detecting dementia after stroke is less well known. In this thesis, I describe and discuss the 
diagnosis of dementia after stroke, with emphasis on the value of screening instruments in 
the diagnosis of poststroke dementia.
In chapter 2, we described which easily obtainable clinical information after acute stroke 
is useful in predicting poststroke dementia. In the Dutch Vascular Factors in Dementia Study 
(DVFDS), a prospective and consecutive hospital-based cohort of acute stroke patients, the 
diagnosis of dementia at 3 to 9 months after the onset of stroke was based on the results 
of an extensive neuropsychological examination, clinical presentation, information from a 
close relative and the score on the Blessed dementia scale. Of the 291 patients, 62 (21%) 
were demented. The final model for early prediction of poststroke dementia included 
age, sex, years of education, previous stroke, white matter lesions on CT scan, neglect, 
hemorrhage on CT scan, mean arterial blood pressure, and atrial fibrillation. ROC analysis 
showed that the area under the curve for this model was 0.82, with a high specificity and a 
moderate sensitivity (resp. 95% and 37%).
Chapter 3 provides an overview of the strengths and weaknesses of existing mental 
status tests in dementia screening in general, and describes the additional considerations 
for dementia screening in patients after a stroke. Although adaptations of existing tests may 
increase their diagnostic value in stroke patients, I end this chapter with the recommendation 
that a screening instrument especially aimed at poststroke dementia should be developed.
We compared the diagnostic accuracy of the CAMCOG and the MMSE in patients with 
a recent stroke in chapter 4. Of 300 consecutive patients aged 55 or over, who were 
included in the DVFDS, 71 (23.7%) were demented 3 to 9 months after their stroke. Sixteen 
severely demented patients were not testable and excluded. The CAMCOG and MMSE 
score were significantly related to dementia (both p<.0001). The CAMCOG was the more 
accurate screening instrument (area under the curve CAMCOG: 0.95 vs. area under the 
curve MMSE: 0.90). Two other clinical variables independently improved the diagnostic 
accuracy of the MMSE and CAMCOG: patients with a left hemispheric lesion had a lower, 
and patients with hemorrhagic stroke a higher chance of being demented. The effect of left 
hemispheric lesion as an independent diagnostic factor could not be explained by selection 
or its association with aphasia alone.
Chapter 5 describes the development of the Rotterdam CAMCOG (R-CAMCOG), based 
on the original CAMCOG. We analyzed the itemscores on the CAMCOG of the patients 
included in the DVDFS. In three steps, the number of items was reduced from 59 to 25, 
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divided over the subscales orientation, memory (recent, remote and learning), perception 
and abstraction. The subscale orientation did not reach statistical significance in a logistic 
regression model, but was included in the R-CAMCOG because of its high face validity in 
dementia screening. Internal validation suggested that the R-CAMCOG and the CAMCOG 
are equally accurate in screening for poststroke dementia (area under the curve is 0.95 
for both tests). A major advantage of the R-CAMCOG, however, is its shorter and easier 
administration.
In chapter 6, we describe the study in which we externally validated the diagnostic 
accuracy of the R-CAMCOG in a new, representative cohort of stroke patients. Of the 121 
patients, 35 (29%) were demented. The diagnostic accuracy at the pre-specified cut-off 
point of 33/34 was established through ROC analyses (sensitivity: 66%, specificity: 94%). At 
a cut-off point of 36/37 sensitivity would be 83% and specificity 78%.
We examined whether the clinical usefulness of the MMSE and the R-CAMCOG could 
be enhanced by an alternative approach in chapter 7. Usually, the results of cognitive 
screening tests for poststroke dementia are interpreted dichotomously by means of a single 
cutpoint, which may lead either to redundant neuropsychological testing, or to unjustified 
reassurance of patients and relatives, all depending on the choice of the cutpoint. This 
calls for the use of two cutpoints. We defined cutpoints below and above which an 
additional neuropsychological examination would not contribute to the diagnosis, because 
the test result indicates a low, or high probability of poststroke dementia. Furthermore, 
we computed the proportion of patients in whom extended neuropsychological testing is 
necessary because of diagnostic uncertainty. The area under the fitted ROC curve did not 
differ between the MMSE and the R-CAMCOG (both tests: 0.895). However, the number 
of additional neuropsychological evaluations necessary for the diagnosis of poststroke 
dementia in a series of 1000 patients would be different for the R-CAMCOG and the MMSE, 
for cutpoints at different levels of diagnostic certainty.
In chapter 8, I discuss some general methodological considerations concerning the 
studies described in this thesis. Furthermore, the role of screening instruments in the 
diagnosis of poststroke dementia is reviewed. Finally, I reflect on the changing diagnostic 
and mechanistic concepts of poststroke dementia. Despite the progress made on the 
redefinition of diagnostic criteria and the differentiation between several subtypes of 
vascular dementia, the diagnosis of poststroke dementia is still a complex one and its 
pathogenesis poorly understood.
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Een beroerte leidt vaak niet alleen tot lichamelijke handicaps, maar ook tot cognitieve 
stoornissen of een dementiesyndroom. Ongeveer 10 tot 40% van de patiënten met een 
recente beroerte ontwikkelt een dementie. De diagnose dementie na een beroerte is niet 
eenvoudig te stellen. Eén van de oorzaken daarvan is o.a. het heterogene karakter van de 
cognitieve stoornissen, die als corticaal of subcorticaal geclassificeerd kunnen worden. Ook 
is een combinatie van de twee mogelijk. Bovendien kan een oordeel over het cognitieve 
functioneren gecompliceerd worden door de somatische symptomen die vaak gepaard 
gaan met een beroerte.
In de klinische praktijk nemen cognitieve screening instrumenten een belangrijke 
plaats in; enerzijds om patiënten te selecteren die in aanmerking komen voor aanvullend 
neuropsychologisch onderzoek, anderzijds als een diagnostisch instrument bij patiënten 
met een duidelijke dementie. De meeste bestaande screening instrumenten die in de 
praktijk worden gebruikt zijn echter ontwikkeld om stoornissen op te sporen die passen bij 
een dementie van het Alzheimer type en hun waarde bij het opsporen van een dementie 
na een beroerte is minder bekend. In dit proefschrift beschrijf ik de diagnose van dementie 
na een beroerte, met nadruk op de waarde van screening instrumenten.
In hoofdstuk 2 beschrijven we welke gemakkelijk verkrijgbare klinische informatie in 
de acute fase na een beroerte bruikbaar is voor het voorspellen van dementie na een 
beroerte. In de Dutch Vascular Factors in Dementia Study (DVFDS), een prospectief cohort 
waarin opeenvolgende patiënten met een acute beroerte werden geïncludeerd, werd de 
diagnose dementie 3 tot 9 maanden na de beroerte gesteld. De diagnose was gebaseerd 
op de resultaten van een uitgebreid neuropsychologisch onderzoek, klinische indruk, 
heteroanamnestische informatie, en de score op de Blessed dementie schaal. Van de 291 
patiënten waren er 62 (21%) dement. Het uiteindelijke model voor vroege voorspelling van 
dementie na een beroerte bevatte leeftijd, geslacht, opleidingsjaren, eerder doorgemaakte 
beroerte, witte stof afwijkingen op CT scan, halfzijdige verwaarlozing, bloeding op CT scan, 
gemiddelde arteriële bloeddruk, en atriumfibrilleren. ROC analyse toonde een gebied onder 
de curve voor dit model van 0.82, met een hoge specificiteit en een matige sensitiviteit 
(resp. 95% en 37%).
Hoofdstuk 3 geeft een overzicht van de sterke en zwakke punten van bestaande cognitieve 
tests in dementie screening in het algemeen. Daarna worden de extra overwegingen bij de 
dementie screening bij patiënten met een beroerte beschreven. Aanpassingen in een test 
kunnen zinvol zijn en de diagnostische waarde verhogen, maar ik besluit dit hoofdstuk 
met de aanbeveling om een screening instrument speciaal voor dementie na een beroerte 
te ontwikkelen.
We vergeleken de diagnostische nauwkeurigheid van de CAMCOG en de MMSE in 
patiënten met een recente beroerte in hoofdstuk 4. Van de 300 opeenvolgende patiënten 
van 55 jaar of ouder die waren geïncludeerd in de DVFDS, waren er 71 (23,7%) dement 
3 tot 9 maanden na de beroerte. Zestien ernstig demente patiënten waren niet testbaar en 
werden geëxcludeerd. De CAMCOG en MMSE scores hadden een significante relatie met de 
aanwezigheid van dementie (beide p<.0001). De CAMCOG was een nauwkeuriger screening 
instrument (gebied onder de curve CAMCOG: 0.95 vs. gebied onder de curve MMSE: 0.90). 
Twee andere klinische variabelen verbeterden de diagnostische nauwkeurigheid van de 
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MMSE en de CAMCOG; patiënten met een linker hemisfeer lesie hadden een kleinere kans 
en patiënten met bloeding hadden een grotere kans om dement te worden. Wat de linker 
hemisfeer lesie als een onafhankelijke diagnostische factor betreft kon dit niet verklaard 
worden door een selectie of de associatie met afasie alleen.
In hoofdstuk 5 beschrijf ik de ontwikkeling van de Rotterdam CAMCOG (R-CAMCOG), 
gebaseerd op de originele CAMCOG. We analyseerden de itemscores op de CAMCOG van 
de patiënten die waren geïncludeerd in de DVFDS. In drie stappen werd het aantal items 
gereduceerd van 59 tot 25, verdeeld over de subschalen oriëntatie, geheugen (recent, ver 
verleden, en leren), perceptie en abstractie. De subschaal oriëntatie bleek geen statistisch 
significante factor in een logistisch regressie model, maar werd toch opgenomen in de R-
CAMCOG vanwege de hoge klinische waarde bij dementie screening. Interne validatie wees 
er op dat de R-CAMCOG en de CAMCOG een gelijke nauwkeurigheid hebben in screening 
voor dementie na een beroerte (gebied onder de curve is 0.95 voor beide tests). Een 
belangrijk voordeel van de R-CAMCOG is de kortere en eenvoudigere afname. Hoofdstuk 6 
bevat de studie waarin we de diagnostische nauwkeurigheid van de R-CAMCOG extern 
gevalideerd hebben in een nieuw, representatief cohort patiënten met een beroerte. Van 
de 121 patienten waren er 35 (29%) dement. De diagnostische nauwkeurigheid op het 
vooraf bepaalde afkappunt van 33/34 werd bepaald middels ROC analyses (sensitiviteit: 
66%, specificiteit: 94%). Bij een afkappunt van 36/37 zou de sensitiviteit 83% zijn en de 
specificiteit 78%.
We onderzochten of de klinische bruikbaarheid van de MMSE en de R-CAMCOG 
verbeterd kon worden door een alternatieve benadering in hoofdstuk 7. Meestal worden 
de resultaten van cognitieve screening tests dichotoom geïnterpreteerd middels één 
afkappunt. Dit kan leiden tot overbodig neuropsychologisch onderzoek bij patiënten die 
evident dement zijn of tot onterechte geruststelling van patiënten en hun familie, afhankelijk 
van het gekozen afkappunt. Dit geeft aanleiding tot het gebruik van twee afkappunten. 
We definieerden afkappunten waaronder en -boven een aanvullend neuropsychologisch 
onderzoek niet zou bijdragen tot de diagnose, omdat de testresultaten een kleine of grote 
kans op dementie aangeven. Daarnaast berekenden we het percentage patiënten bij wie 
een neuropsychologisch onderzoek nodig is vanwege de diagnostisch onzekerheid. Het 
gebied onder de ROC curve verschilde niet tussen de MMSE en de R-CAMCOG (beide tests 
0.895). Het aantal aanvullende neuropsychologische onderzoeken dat nodig is voor de 
diagnose dementie na een beroerte in een serie van 1000 patiënten was echter verschillend 
voor de MMSE of de R-CAMCOG, afhankelijk van het gekozen niveau van diagnostische 
zekerheid. In hoofdstuk 8 worden algemene methodologische overwegingen besproken 
die betrekking hebben op de studies uit dit proefschrift. Daarna bespreek ik de rol van 
screening instrumenten in de diagnose dementie na een beroerte. Tot slot ga ik in op 
de veranderende diagnostische en pathogenetische concepten van dementie na een 
beroerte. Ondanks de voortgang die gemaakt is, bijvoorbeeld bij het herdefiniëren van 
de diagnostische criteria en het maken van onderscheid tussen verschillende vormen van 
vasculaire dementie, is dementie na een beroerte nog altijd moeilijk te diagnosticeren en 
de onderliggende pathogenese grotendeels onbegrepen.
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